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Abstract 
Statistical Modeling in the Optimization of Breast Cancer 
Screening Schedules 
by 
Charlotte Hsieh Ahern 
Although screening for breast cancer is broadly utilized in the United States, 
the optimal approach in terms of examination modality, frequency, and starting age 
is unclear. Furthermore, there is no consensus on the benefit from earlier, more 
frequent, or additional modes of screening for women with high-risk for breast cancer. 
This thesis explores methods for finding optimal screening strategies by modeling 
the costs and benefits of breast cancer screening programs through a simulation-
based and a theoretical approach, which incorporate some ignored or unexplored 
components. For the general population, cost-effectiveness studies evaluating breast 
cancer screening have focused on mammography alone, and have not assessed the 
impact of its combination with clinical breast exam, a cheaper and more practical 
exam. Costs incurred beyond screening including costs for work-up, biopsy, and 
treatment have often been ignored. We account for these factors in a comprehensive 
microsimulation analysis by modeling the natural history of the disease including age-
specific incidence, sojourn time, and exam sensitivity and specificity, and evaluate 
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the cost-effectiveness of a set of screening programs on a simulated cohort of women. 
Similarly, we focus on a special case of high-risk women where we include screening 
programs that begin at an earlier age, have more frequent examinations, and include 
combinations of magnetic-resonance imaging, which has recently been recommended 
for women at high-risk for breast cancer. The most cost-effective approach depends on 
how much society is willing to pay to save a year of life. Finally, we take a theoretical 
approach which is motivated by the idea that other optimal screening programs may 
exist outside a set of predetermined strategies used in a simulation-based approach. 
While empirical studies give a better idea of which screening schedules are useful, a 
theoretical approach may uncover a true optimal schedule. We assume a nonstable 
disease model and account for costs of screening and dollar value of benefit in a utility 
function under two different frameworks to estimate the optimal number or ages of 
examinations given certain general assumptions. We show that a solution exists for 
these models and demonstrate in numerical studies that they will give reasonable 
results. 
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Chapter 1 
Introduction 
Breast cancer is the leading cancer for women in the United States. Screening for 
breast cancer is important in the early detection of the disease, which may lead to 
longer survival when combined with effective treatments. While screening is broadly 
utilized in the United States, the optimal approach in terms of examination modal-
ity, frequency, and starting age of screening for women of average-risk and high-risk 
remains unclear. This thesis intends to explore statistical methods for finding opti-
mal screening strategies by modeling the costs and benefits of various breast cancer 
screening programs through a simulation-based approach and a theoretical approach, 
which incorporate some ignored or unexplored components. 
1.1 Simulation-Based Approach 
Mammography and clinical breast exam are common examples of screening for the 
presence of breast cancer. However, cost-effectiveness studies evaluating breast cancer 
screening in an average-risk cohort have focused on mammography alone, and have 
not assessed the impact of the combination of the modalities of mammography and 
clinical breast exam. In addition, most analyses have been limited to screening exam 
costs and have not accounted for subsequent costs for work-up examinations, biopsies, 
or treatment and maintenance costs, and do not directly account for false-positive 
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examinations. We incorporate these overlooked components into a simulation model. 
It is also important to distinguish between average-risk and high-risk cohorts, as 
the optimal screening strategy may not be the same for both groups due to differences 
in incidence rate, tumor characteristics, screening modalities, and so forth. No official 
guidelines currently exist for screening among high-risk women, however, screening 
with magnetic resonance imaging (MRI) has recently been discussed as a requisite 
mode of screening for women with high-risk for breast cancer. 
We conduct separate cost-effectiveness analyses for average-risk and high-risk co-
horts of women by simulating their natural histories of disease and then assessing 
the impact of screening on their survival and accrual of costs. Investigated screening 
strategies included the modalities of mammography and clinical breast exam, with 
the addition of MRI for the high-risk cohort. 
1.2 Theoretical Approach 
In contrast to the broad attention to modeling the general screening process in a 
simulation-based approach, less attention has been paid to the optimization of exam-
ination schedules for screening examinations using mathematical models. Although a 
simulation approach allows for the exploration of multiple specific screening programs, 
none of them are necessarily optimal for any given utility function. This theoretical 
approach is motivated by the idea that other optimal but unexplored screening pro-
grams may exist. Under a theoretical framework, a mathematical model of the costs 
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and benefits of a screening program may be used to determine the optimal ages and 
spacing of examinations, or the optimal number of examinations within a specified 
screening horizon. 
A utility function has previously been proposed under the assumption that pre-
clinical disease incidence is independent of age under the stable disease model (Zelen 
1993). We generalize this approach by Zelen and propose a model which reflects an 
age-dependency in the transition into the preclinical state and also incorporates a 
cost component. We show that under two separate frameworks, an optimal solution 
exists, and give some numerical results as examples. 
1.3 Outline 
The content of this work is organized as follows. We introduce and review cost-
effectiveness analysis and previous works for women at average risk for breast cancer 
(referred to as the average-risk cohort) in Chapter 2, with a description of the present 
work's model, data inputs, and results. In Chapter 3, we extend the analysis to 
women with high risk for breast cancer (referred to as the high-risk cohort) and 
describe changes to the original model and present the results. Next, in Chapter 4, 
we review other works in the mathematical modeling of optimal screening strategies 
and present two proposed frameworks with proofs and results. Finally, we conclude 
this work with a summary of findings and a discussion of possible future work. 
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Chapter 2 
Microsimulation Model: Average Risk Cohort 
2.1 Background 
Breast cancer remains the most common malignancy affecting women in North Amer-
ica. Early detection and effective treatment of the disease may significantly reduce 
mortality rates. In fact, the rate of death from breast cancer in U.S. women decreased 
between 1990 and 2000, while the incidence of the disease increased[l]. It has been 
shown that early detection and effective treatments for the disease have contributed 
to the observed decline in the rate of death from breast cancer[2]. 
Screening examinations such as mammography and clinical breast exam are com-
mon examples of screening for the presence of preclinical breast cancer. Despite broad 
utilization, there is no consensus on the approach to screening, including frequency, 
starting age, and examination modality. For example, the American Cancer Society 
(ACS) recommends annual mammography screening for women ages 40 and older, 
clinical breast exam triennially beginning at age 20, and annually beginning at age 
40[3]. The National Cancer Institute (NCI) recommends screening mammography 
every 1-2 years[4], and the U.S. Preventive Services Task Force (USPSTF) recom-
mends screening mammography, with or without clinical breast examination, every 
1-2 years for women aged 40 and older[5]. Because of the existing controversy over 
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the most appropriate screening strategy, it is important to evaluate various screening 
strategies to determine the optimal strategies in terms of costs and benefits. 
It is difficult to evaluate screening strategies since many factors related to screen-
ing exist, such as the relative advantage of early detection compared to waiting for 
symptoms to manifest without screening, the preclinical sojourn time distribution, 
and competing causes of mortality. Also, it is clear that early detection trials are 
very difficult to carry out in terms of size of the trial, length of follow-up, and com-
pliance issues. Conducting future breast cancer early detection trials to evaluate 
various screening strategies among different age cohorts is difficult and unlikely, for 
ethical and economic reasons. On the other hand, data collected from completed large 
randomized early detection trials and other observational studies present a unique op-
portunity to evaluate and compare different screening strategies in order to find the 
optimal ones, by using microsimulation methods. 
Computer based simulation models are useful and popular tools in the system-
atic evaluation of the effectiveness of various cancer screening programs, including 
breast, cervical, and lung cancers[6, 7, 8, 9, 10, 11]. Microsimulation models use 
Monte Carlo methods to model the cost and effectiveness of screening in a screening 
cohort. The life history of each subject is simulated, and disease progression can be 
modeled according to previously published natural history models[12, 13, 14], based 
on the probability distribution of each event. Such simulations are performed for a 
large number of subjects producing outputs of interest such as life expectancy and 
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costs. The natural histories of each woman in a birth cohort may be generated by uti-
lizing evidence from available sources such as completed clinical trials and previously 
published mathematical models and analyses. 
Eight major randomized early detection trials have been carried out in North 
America and Europe evaluating the early detection of breast cancer using mammog-
raphy with or without clinical breast exam, beginning with the Health Insurance 
Plan (HIP) of New York in 1963. The trials that followed were the Edinburgh study, 
the Swedish Two-County studies, Malmo, Stockholm, Gothenburg, and the Cana-
dian National Breast Screening Studies (CNBSS). The HIP, Edinburgh, and CNBSS 
trials offered both modalities of screening: mammography and clinical breast exam, 
while the remaining trials focused on mammography alone. Overall, evidence of ben-
efit from screening varied across these randomized clinical trials [15], and findings 
led to controversy regarding the relevance of the suggested benefits for individual 
women[16, 17, 18, 19]. The discrepancies in the evidence may be explained by dif-
ferences in trial design, screening schedules, and age cohorts. Rather than directly 
drawing inferences based on these trials alone, we use data obtained from these trials 
as data inputs in a microsimulation model to evaluate various screening programs by 
adding uncertainties. 
Optimal screening strategies must balance the tradeoff between mortality reduc-
tion and the associated costs and burdens to society. Although two of the major 
guidelines suggest clinical breast exam in combination with mammography, almost 
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all literature in breast cancer screening addressing the balance between mortality re-
duction and costs have focused on mammography only[20, 21, 22, 23, 24, 25, 26, 27, 
28, 29, 30, 31], and have paid less attention to the combined use of mammography 
with clinical breast examination. 
However, recent studies have shown that periodic clinical breast exam combined 
with mammography improves the overall sensitivity compared with mammography 
alone[32, 33, 34, 35]. As a routine part of a woman's recommended annual well-
woman physical examination, clinical breast examinations are easy to administer 
and generally cheaper than mammography, making them a sensible complement to 
mammography. Shen and Parmigiani[7] found that biennial mammography coupled 
with an annual clinical breast examination can be a cost-effective strategy compared 
to forty-seven alternative screening strategies. However, only the cost of screening 
examinations was used in their cost-effectiveness analysis. 
To date there is little research evaluating the cost-effectiveness of breast cancer 
screening programs combining both mammography and clinical breast exam while 
incorporating costs other than screening examinations, including costs of diagnostic 
follow-up due to abnormal examinations, treatment, and maintenance costs after di-
agnosis. While some studies of breast cancer screening have included treatment costs 
subsequent to diagnosis[26, 27, 28, 20, 25, 30, 36, 37], they have often been limited to 
specific age cohorts or subgroups, such as women older than 65, or African American 
women. For example, Mandelblatt et al. [28] investigated optimal screening strategies 
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using mammography for older women including costs of screening, treatment, and 
care. While these studies incorporate costs beyond screening, only one accounts for 
a general added cost due to false-positive mammography, and none of them consider 
the combination of screening modalities of mammography and clinical breast exam, 
or the direct cost of biopsy. 
Because these components may play important roles in the cost-effectiveness of 
a screening program, they should not be neglected. Therefore, it is of interest to 
account for the above components in a comprehensive microsimulation analysis to 
determine which strategies are cost-effective. For each investigated screening strategy, 
the direct medical costs include the cost of screening examinations, the cost of work-up 
examinations for positive or abnormal exams, the cost of necessary and unnecessary 
biopsies due to true and false positive examinations, and the costs incurred from 
treatments after diagnosis. The measure of benefits used are the expected quality-
adjusted life years (QALYs). 
2.2 Model and Data Inputs 
The continuous time simulation model follows the general structure of Shen and 
Parmigiani[8] with modifications to incorporate false-positive examinations and sub-
sequent interventions following screening. The general model structure may be vi-
sualized in Figure 2.1. Data inputs for each component of the simulation model are 
estimated from existing data from published studies or randomized breast cancer 
Asympto-
matic 
cohort 
screening 
Detected S^  
Clinically 
Detected 
$ 
Work-up 
M 
$ $ 
Treatment 
1 Never 
J Detected 
g 
remain preclinical Death 
(other) 
followed until death Death 
(other) 
False-
Positively 
Detected 
$ 
Work-up 
(False +) 
$ 
Biopsy (-) Death (other) 
Figure 2.1 : Model structure for evaluating costs of screening, work-up, biopsy, and 
treatment for breast cancer. 
screening trials. We discuss each component of the model below. See Table 2.1 for a 
list of references for each model component. 
We considered ten screening strategies, plus a strategy of no screening, listed in 
Table 2.2. The selected strategies focus on realistic screening intervals, and include the 
recommended strategies from the ACS, NCI, and USPSTF. We varied time intervals 
between exams in different age cohorts in some strategies to accommodate the age-
dependency of incidence, sensitivity, and sojourn time. 
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Model 
Components 
Natural History 
Screening Impacts 
Costs Related to 
Screening, Workup, 
and Treatment 
Indirect Costs 
Survival Models 
Data Inputs 
Age-Specific Incidence 
Age-Specific Pre-clinical Transition 
Sojourn Time Distributions 
Tumor Growth Distributions 
Mammography Sensitivity (by age and tumor size) 
Mammography Specificity (by age) 
Clinical Breast Exam Sensitivity, Specificity 
Diagnostic Mammography Sensitivity, Specificity 
Mammography and Clinical Breast Exam 
Diagnostic Mammography 
Breast Biopsy 
Treatment by Stage 
Lost Productive Time (lost wages) 
By Age, Tumor Size, Nodal Status at Diagnosis, 
ER status, and Treatment 
Competing Risks by Age 
Quality of Life Adjustments by Treatment 
References 
[38] 
[6, 39] 
[32, 40] 
[41] 
[42] 
[43] 
[44] 
[45] 
[46, 47] 
[46] 
[46] 
[27] 
[48] 
[6, 49, 50, 51] 
[52] 
[53] 
[6, 54] 
Table 2.1 : Model components and data inputs for average-risk analysis. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
MM intv(age) 
1(40-79) 
2(40-79) 
2(40-79) 
2(40-79) 
1(40-79) 
l(40-49),2(50-79) 
l(40-59),2(60-79) 
1(40-69) ,2(70-79) 
2(40-49),l(50-79) 
1(40-79) 
CBE intv(age) 
2(40-79) 
2(41-79) 
1(40-79) 
1(40-79) 
1(40-79) 
1(40-79) 
1(40-79) 
1(40-79) 
3(20-39),1(40-79) 
MM=Mammography; CBE=Clinical Breast Exam; 
intv=interval between exams; age=age range 
Table 2.2 : Screening strategies investigated for the average-risk cohort. 
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The outcomes were the expected QALYs and expected total medical costs per 
woman, each discounted at 3% annually beginning at age 20. We compared screening 
strategies using incremental cost-effectiveness ratios in an incremental analysis [55, 56]. 
2.2.1 Natural History Model 
We generate a birth cohort of 500,000 women by Monte Carlo simulation, where the 
cohort size is chosen so that the standard errors of the gain in QALYs compared 
to no screening is less than 0.2 daysn for all ten strategies. Each woman's natural 
history is simulated independently. Prevalent cases are simulated according to age-
specific incidences of breast cancer. Among women who develop breast cancer, we 
generate their natural histories of the disease over time. In the natural history model, 
we assume four relevant states of the progressive disease, as described by Zelen and 
Feinleib[12]: disease-free or asymptomatic state (H); detectable pre-clinical state (P); 
clinical state (C); and death state (D). For women who have the disease, we simulate 
their preclinical duration and ages at onset of clinical disease based on an assumed 
distribution and published data, respectively; and survival time, based on simulated 
age and tumor characteristics at detection. 
The latent ages at onset of preclinical disease must be derived given age-specific 
incidence of clinical disease and preclinical sojourn time. We may easily obtain the 
age-specific incidences of breast cancer which are observable and well-documented, 
and we use age-specific estimates from an analysis by Moolgavkar et al.[38]. On the 
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other hand, transition into the preclinical state is an unobservable event. We must 
therefore numerically derive the age-specific incidences of preclinical disease through 
a deconvolution approach described in Parmigiani[6] given the age-specific incidence 
of clinical disease at age y (Ic(y)) and the sojourn time distribution (wpc(y — t\t)), 
where t is the age of transition from H to P , and y — t is the time spent in P . The 
instantaneous probability of transition from P to C at age y is: 
ry 
Ic{y) = / whp(t)wpc(y - t\t)dt, 
Jo 
where t%>(£) is the instantaneous probability of transitioning from H to P at time 
t. Using a method by Parmigiani and Skates [39], the age-specific transition rate Whp 
may be estimated from the convolution relationship above. 
Our choice for the sojourn time distribution is based on the commonly used expo-
nential distribution[57, 58, 59], which was shown to be a satisfactory fit in an analysis 
of the HIP database[40]. In our simulations, we assume an exponential sojourn time 
distribution with an age-dependent component where the mean sojourn time, n(t), 
depends on age at onset of preclinical disease. Uncertainty is incorporated through an 
inverse gamma prior for fj, with scale and shape parameters that match the estimated 
mean and standard deviation from the CNBSS trials, where the mean sojourn time 
(and standard deviations) for ages < 50 was 1.9 (1.2) years, and 3.1 (0.94) years for 
ages > 50 [32]. Thus, a random sojourn time is simulated for each subject depending 
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on her age at onset of preclinical disease. 
We modeled tumor growth by tumor volume-doubling time under the exponen-
tial growth model[41]. We assume that the threshold diameter for a tumor to be 
detectable by screening is 0.5cm[60], and that the diameter at which breast can-
cer becomes clinically manifested is 2cm or more, based on data from the CNBSS 
trials [61]. Depending on the number of tumor volume doublings between the min-
imum detectable tumor volume and the clinically symptomatic tumor volume, we 
calculate the doubling time (DT) for each woman as a quotient of the woman's so-
journ time and the number of doublings. We then obtain each woman's tumor volume 
at diagnosis (TV), a random quantity which depends on the woman's individual time 
spent in the preclinical state at the time of detection (time in P): 
TV = (minVol) * 2*doublin9S 
= (minVol) * 2 DT
 ? 
where minVol is the minimum detectable tumor volume. 
2.2.2 Screening Impacts and Diagnostic Procedures 
Because there is evidence that the sensitivity of mammography depends on tumor 
size and age at screening[32, 62, 63, 60, 42, 35], we model such a dependency using a 
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logit model: 
exp(a0 + ai(t - 40) + a2(rf - 1)) 
W>a> ~ l + exp(a0 + a i ( t - 4 0 ) + a 2 ( d - l ) ) ' 
where t is age at diagnosis, and d is tumor diameter in cm. The coefficients of the 
logit model for mammography are determined based on sensitivity estimates from an 
analysis by Kolb et al. (2002) [42]. For example, we let a sensitivity for mammography 
of 0.58 correspond to a woman at age 40 with a tumor diameter of 1cm; a sensitivity 
of 0.1 correspond to a woman of the same age but with a tumor diameter of 0.05cm; 
and a sensitivity of 0.83 correspond to a woman age 65 with a tumor diameter of 1cm. 
Then /?MM(40, 1) = 0.58, PMM(40, 0.05) = 0.1, /3MM(65,1) = 0.83 and the coefficients 
of the logit model are ao = 0.323, a.\ = 0.051, and a? = 2.653 for mammography. 
Because insufficient evidence indicates that clinical breast exam sensitivity depends 
on age or tumor size, we used a constant value for clinical breast exam sensitivity 
(PCBE = 0.541) taken from Elmore et al. (2005) [44]. To account for random variation 
in sensitivity within the cohort we used a beta prior distribution for each sensitivity 
so that each woman receives a random sensitivity depending on her age or tumor 
size at time of examination. Using an effective sample size (s) of SMM = 30 for 
mammography and SQBE = 40 for clinical breast exam, the parameters a and b of the 
Beta(a, b) distribution for mammography are a = @MM * SMM and b = (1 — (3MM) * 
SMM, and a = 0CBE * SCBE and b = (1 — PCBE) * SCBE for clinical brast exam, so that 
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the variance of the distribution is larger for mammography, consistent with previous 
screening trials [32, 44]. 
We similarly model age-dependent false-positive rates (7) for mammography and 
clinical breast exam at screening using false-positive rate estimates reported in the 
literature[43, 44], with 7MM(50) = 0.076 and 7MM(70) = 0.048, and ^CBE = 0.10. 
Again, we use a logit function for mammography as above, using these reported 
estimates but depending on age only. Random variation within the cohort is again 
accounted for using a beta prior distribution on the false-positive rate of each screening 
modality, where SMM = 30 and SCBE = 40. 
According to the National Comprehensive Cancer Network Breast Cancer Screen-
ing and Diagnosis Guidelines, women with positive or abnormal screening examina-
tions are recalled for further work-up[64]. A recalled woman receives a diagnostic 
mammography or ultrasound, then biopsy (the gold standard) if the diagnostic test 
is positive[64]. The recall rate after a positive or abnormal initial screening exam-
ination ranges from 1-17%[65, 66]. We used diagnostic mammography as the form 
of work-up, with sensitivity {fidMM = 0.80) and specificity (<WM = 0.90) estimates 
from the Breast Cancer Surveillance Consortium [45]. For a woman whose tumor 
is detected symptomatically, a diagnostic mammography and breast biopsy are also 
given to confirm the disease status. Women in the preclinical state who are never 
diagnosed are assumed to have died of other causes. 
The overall sensitivity and false-positive rate using both mammography and clini-
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cal breast exam were calculated assuming the independence of the two modalities. It 
has been shown from analyses of data from the HIP and CNBSS trials that mammog-
raphy and clinical breast exam contribute independently to the detection of breast 
cancer [67]. Then the overall sensitivity of a screening program using both mammog-
raphy and clinical breast exam is calculated: 
0{t,d) = pMM(t,d) + /3cBE{t,d)-(3MM(t,d)PcBE(t,d), 
A similar model is assumed for false-positive rates of the two screening modalities. 
Table 2.3 : Mean values of observed sensitivity (Sens.), specificity (Spec), and recall 
rate (RR) for various age groups. 
Age 
40-49 
50-59 
60-69 
Mammography 
Sens. 
0.6603 
0.7460 
0.8278 
Spec. RR 
0.9141 0.0860 
0.9311 0.0690 
0.9452 0.0550 
Clinical Breast Exam 
Sens. Spec. RR 
0.5385 0.9400 0.0601 
0.5391 0.9400 0.0602 
0.5420 0.9402 0.0600 
Mammography &c 
Clinical Breast Exam 
Sens. Spec. RR 
0.8419 0.8593 0.1408 
0.8836 0.8754 0.1247 
0.9211 0.8878 0.1124 
2 . 2 . 3 T r e a t m e n t and Prediction of Survival 
Because treatment options vary with a patient's tumor characteristics at diagnosis, 
the cost of treatment is different according to disease stage at diagnosis. For patients 
diagnosed with breast cancer, we record their simulated tumor size and age at time of 
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diagnosis. A predictive Poisson linear model based on tumor size and age at diagnosis 
was developed using SEER registry data[53] to predict the number of nodes involved 
at diagnosis. A truncated Poisson distribution was then used to constrain the number 
of nodes involved in a screen-detected case to be less than or equal to that of the same 
case at the expected time of clinical manifestation. 
Given tumor size and number of nodes, stage of disease was determined using the 
tumor-node-metastasis staging system[68]. Patients with positive nodal involvement 
were considered to have metastatic disease (stage III/IV) if their tumor had a diameter 
greater than 5 cm at diagnosis; otherwise they were considered to have stage IIB 
cancer if their tumor diameter was less than 5 cm. Patients with node-negative 
tumors were considered to have stage I or IIA disease if the tumor diameter was less 
than or equal to 2 cm, or greater than 2 cm, respectively. 
According to treatment guidelines, patients with stage I to IIIA breast cancer 
should receive breast conserving surgery (BCS) or mastectomy with or without ra-
diation. We simulated surgery and radiation procedures according to recent studies, 
given disease stage at diagnosis [69, 70]. Administration of tamoxifen, chemotherapy, 
or a combination of the two was simulated in accordance with observed U.S. dissem-
ination patterns based on age, stage of disease, and ER status at diagnosis[52]. Due 
to limited knowledge of the connection of ER status with other risk factors, ER sta-
tus is simulated independently, allowing about 70% of the tumors to be ER positive, 
according to the general population[71]. 
Treatment 
Tamoxifen 
ER pos 
ER neg 
Chemotherapy 
Tamoxifen+Chemo 
ER pos 
ERneg 
Age 
0.28 
0 
0.27 
0.47 
0.27 
< 50 Age 50-59 
0.28 
0 
0.14 
0.38 
0.14 
Age > 60 
0.28 
0 
0.08 
0.34 
0.08 
Table 2.4 : Reduction in mortality hazard ratio due to treatment effects. 
Treatment type 
No treatment 
Tamoxifen 
Chemotherapy 
Tamoxifen+Chemo 
Months 1-6 
1 
0.99 
0.60 
0.99*0.60 
Months 7-12 
1 
0.99 
0.90 
0.99*0.90 
Year 2 
1 
0.99 
0.99 
0.99*0.99 
Years 3-5 
1 
0.99 
0.99 
0.99*0.99 
Remainder 
1 
1 
0.99 
0.99 
Table 2.5 : Quality-of-life adjustment factors used in analysis based on treatment. 
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To estimate survival, measured from the time of diagnosis, we used a Cox re-
gression model on age, ER status, primary tumor size, and number of nodes at di-
agnosis. We estimated covariate coefficients (exp(/3age) — 1.008, exp(/?£#) = 0.669, 
exp(/3tvoi) = 1.063, exp(/3nodes) = 1.038) in the predictive survival model based on a 
combined analysis of four Cancer and Leukemia Group B trials [6, 49, 51, 50]. We 
used hazard reduction estimates due to treatment effects [52] and quality of life ad-
justments according to the type of adjuvant treatment[72, 54], listed in Tables 2.4 
and 2.5. 
The woman may die from breast cancer or from other competing causes, where 
death from other causes is based on actuarial tables using a 1960 birth cohort from the 
census database [53]. If her estimated breast cancer survival time is shorter than her 
simulated natural lifetime, then she is assumed to die from breast cancer. Otherwise, 
she dies from other competing risks. In addition, any woman who never enters the 
clinical stage is assumed to die from other causes. 
2.2.4 Costs 
Total medical costs (Table 2.6) included costs of mammography and clinical breast 
exam, diagnostic mammography, biopsy, and treatments. The cost of biopsy was 
a weighted average of costs of common biopsy procedures [46]. We included costs 
of primary surgery (BCS or mastectomy with or without radiation), and adjuvant 
chemotherapy and/or tamoxifen as part of the initial phase of care, followed by con-
20 
Table 2.6 : Direct costs due to breast cancer screening, diagnosis (work-up and biopsy), 
and treatment according to stage and type of surgery (year 2004 dollars). The initial phase 
of care includes any adjuvant chemotherapy. 
Cost C o m p o n e n t s Cost ($) Ref. 
Screening-related Costs 
Mammography (bilateral) 
Clinical Breast Exam 
Diagnostic Mammography 
(Unilateral) 
Breast Biopsy 
Treatment-related Costs 
Tamoxifen/ 5yr. 
Adjuvant Chemotherapy/lyr. 
(initial phase) 
Monthly Costs by Phase and Stage 
83 
47 
78 
832 
7,553 
5,618 
Treatment Phase 
Initial Phase 
1 
II 
III/IV 
Continuing-Care Phase 
I 
II 
III/IV 
Terminal Phase (BC death) 
I 
II 
III/IV 
BCS 
1,611 
2,636 
-
287 
344 
-
3,904 
2,936 
-
BCS 
-l-rad. 
2,688 
3,088 
3,391 
185 
197 
681 
3,071 
3,810 
3,773 
Mast. 
2,228 
2,895 
3,119 
250 
252 
233 
3,945 
3,247 
3,315 
Mast. 
-l-rad. 
3,228 
3,895 
4,119 
250 
252 
233 
3,945 
3,247 
3,315 
Monthly Terminal Phase Costs 
(non-BC) 
2,775 
[46] 
[47] 
[46] 
[46] 
[27] 
[27] 
[27] 
[73] 
Ref = reference number corresponding to cost estimate;BCS = breast conserving surgery; Mast, 
mastectomy; +rad. = (a primary treatment) plus radiation therapy; BC = breast cancer 
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tinuing care, and terminal phase care[27]. The initial phase included the first twelve 
months after diagnosis, and the terminal phase covered the last twelve months before 
death. The continuing-care phase included the duration between the end of the initial 
phase and beginning of the terminal phase, or a maximum of 25 years if the woman 
dies from competing risks. We included indirect costs from lost productive time 
through lost wages by age[48] for women who die prematurely from breast cancer. 
We converted all costs to year 2004 U.S. dollars using the medical care component of 
the Consumer Price Index[74]. 
2.2.5 Incremental Cost-Effectiveness Analysis 
We used an incremental analysis to reflect the relative cost-effectiveness of the screen-
ing strategies among one another. This method allows us to assess the cost of using 
one strategy in preference to another. Screening strategies were rank-ordered by in-
creasing cost, and we used simple dominance to rule out strategies that are more 
costly but less effective than an alternative. The incremental cost-effectiveness ratio 
(ICER) was calculated for each strategy by dividing the difference in cost by the 
difference in benefit compared with the next least-expensive strategy. Strategies with 
lower effectiveness and higher ICER were ruled out by extended dominance and the 
ICER was recalculated after their elimination[56]. ICERs for the strategies not ruled 
out by dominance (efficient or cost-effective strategies) are interpreted as the ratio of 
additional cost per QALY saved compared to the next least-expensive alternative. 
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2.2.6 Sensitivity Analysis 
We conducted two 1-way sensitivity analyses. Because average sensitivity and speci-
ficity values for community-based clinical breast exam may be different from esti-
mates obtained in randomized clinical trials, we used a lower sensitivity of 0.276 and 
a higher specificity of 0.994, according to community-based estimates[44]. In a sepa-
rate sensitivity analysis, we predicted survival using age- and stage-specific estimates 
calculated from the SEER database, which have been used in the Cancer Interven-
tion and Surveillance Modeling Network models[75]. In contrast to the original model, 
detailed tumor characteristics do not individually contribute to the survival estimate. 
2.3 Results 
The results (Table 2.7) showed that although every screening strategy extended life 
expectancy compared to no screening, some were more efficient with a lower cost 
per QALY saved than the alternatives: strategies B, D, G, I, and J, in order of 
increasing expense. Among them, biennial mammography and clinical breast exam 
in alternating years from ages 40-79 (B) saved about 13 days of life for an additional 
$1,200, equivalent to $32,700 to save a year of life compared to no screening. The next 
cost-effective alternative was strategy D, with biennial mammography and annual 
clinical breast exam from ages 40-79, which saved 1.5 additional days of life for $500, 
compared to strategy B. By replacing biennial with annual clinical breast exam in 
strategy B, it costs $99,500 to save an additional year of life compared to strategy 
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B. The most expensive strategy J saved only a half day for an additional $5,500 
compared to strategy I, with a very high ICER of over $3.8 million per QALY saved. 
Other strategies were eliminated by simple or extended dominance because of their 
inefficiency. 
The tradeoff between total costs and expected QALYs for each screening strategy 
is visualized in a tradeoff plot (Figure 2.2), corresponding to the results in Table 2.7. 
Dominated strategies fall below the line connecting the non-dominated alternatives, 
representing the efficiency frontier. The most expensive (and effective) strategy J, on 
the upper right corner of the efficiency frontier, is the current recommendation from 
the ACS. Compared to the alternatives, the gain in QALYs is small considering the 
large cost difference. 
In a separate plot (Figure 2.3), we show the standard errors of the mean gain in 
QALY and mean total cost difference compared to no screening. Although strategies 
F and H do not directly fall on the line of efficiency, their standard errors indicate 
that they may still be cost-effective in spite of the small absolute deviation from the 
efficiency frontier. 
Sensitivity Analysis 
When alternative sensitivity and specificity values were used for clinical breast exam, 
the results showed lower overall gains in QALYs and costs compared to the original 
analysis (Table 2.8). These changes may be explained by a delay in disease detection 
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Table 2.7 : Results of cost-effectiveness analysis including screening, biopsy, and treatment 
costs. Costs and QALYs are discounted at 3%. Strategies that are dominated or eliminated 
through extended dominance are indicated with '—'. 
Strat 
X 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
MM intv(age) 
— 
2(40-79) 
2(40-79) 
1(40-79) 
2(40-79) 
1(40-49), 
2(50-79) 
1(40-59), 
2(60-79) 
2(40-49), 
1(50-79) 
1(40-69), 
2(70-79) 
1(40-79) 
1(40-79) 
CBE intv(age) 
— 
2(40-79) 
2(41-79) 
1(40-79) 
1(40-79) 
1(40-79) 
1(40-79) 
1(40-79) 
1(40-79) 
3(20-39) 
1(40-79) 
Total 
Cost ($) 
13,100 
14,300 
14,300 
14,600 
14,700 
15,000 
15,200 
15,200 
15,300 
15,400 
20,900 
QALYs Incremental 
(years) QALYs gained 
27.3936 
27.4254 — 
27.4306 0.0370 
27.4316 — 
27.4346 0.0040 
27.4350 — 
27.4364 — 
27.4368 0.0022 
27.4371 — 
27.4376 0.0007 
27.4390 0.0014 
ICER 
— 
32,700 
— 
99,500 
197,900 
330,000 
3,839,800 
MM=Mammography; CBE=Clinical breast exam; intv—interval between examinations (years) 
Total Cost: Mean total cost per woman in the complete cohort, rounded to the nearest $100 
QALYs! Mean total expected quality-adjusted life years per woman from age 20 
ICER: Incremental cost-effectiveness ratio (incremental cost/incremental QALYs gained compared 
to next least-expensive strategy) 
Current recommended strategies are shown in boldface: A=NCI/USPSTF; C=NCI; 
I=NCI/USPSTF; J=ACS 
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caused by the lower exam sensitivity, which leads to shorter survival. The reduction in 
medical costs is a result of fewer unnecessary work-ups and biopsy procedures due to 
the higher specificity. It is not surprising that strategy C, which does not use clinical 
breast exam and was not cost-effective before, became more cost-effective, since using 
clinical breast exam as a complement to mammography is less effective when the 
sensitivity of clinical breast exam is low. The higher frequency of mammography 
becomes more important in strategies complemented by clinical breast exam, which 
explains why strategies D and G, which were cost-effective in the original analysis, 
become dominated. 
Under the alternative survival model, the gain in QALYs compared to no screen-
ing appears smaller than that in the original analysis. Because disease stages do not 
capture detailed tumor characteristics, this model may not predict survival as accu-
rately as the original model, which may explain the observed difference in survival. It 
is likely for a woman to be defined in the same disease stage at screening and clinical 
detection, despite any progression in tumor size or nodal status, making the survival 
estimates in both cases more similar. Compared to the original analysis, strategies 
C and H shifted and became cost-effective, while strategies G and I were not. This 
may be explained by the underestimation of survival which may cause those strategies 
giving mammography alone (C) or with less frequent screening (H) to become more 
comparable to strategies using both mammography and clinical breast exam (G) or 
that have more frequent screening (I). 
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2.4 Discussion 
This study is the first to comprehensively evaluate the cost-effectiveness of the com-
bined use of mammography with clinical breast exam in breast cancer early detection 
while accounting for costs of screening, work-up, biopsies due to true or false-positive 
examinations, and treatments. We assessed current recommended guidelines from 
three major cancer organizations and compared them with other realistic strategies 
that combine mammography and clinical breast exam with different starting ages and 
intervals. 
Compared to the alternatives, two of the recommended strategies are cost-effective 
in general: the NCI/USPSTF recommendation of annual mammography and clinical 
breast exam from ages 40-79, and the most effective but expensive recommendation 
from the ACS that begins clinical breast exam at age 20, followed by mammogra-
phy and clinical breast exam from ages 40-79. The NCI/USPSTF recommendation 
of annual mammography alone from ages 40 to 79 is cost-effective when the sensi-
tivity of clinical breast exam is low, according to community-based settings. The 
NCI/USPSTF guideline of mammography with clinical breast exam every two years 
was not an efficient strategy. A more cost-effective alternative is to provide mam-
mography and clinical breast exam in alternating years, which leads to more savings 
in QALYs with similar costs. Alternating exam years allows for annual examinations 
with one of the two screening modalities. 
The strategy recommended by the ACS was the most expensive and effective. If 
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society is willing to pay the required costs to save an additional QALY, this strategy 
is favorable. Alternatively, the cheapest but also effective alternative would be to 
offer biennial mammography and clinical breast exam alternatively from ages 40-79 
(strategy B). 
Among all the strategies, only strategy B fell under the commonly accepted cost-
effectiveness threshold of $50,000/QALY[76, 36]. Although this strategy is not as life 
saving as some other alternatives, the gains in QALYs for the other efficient strategies 
D, G, I, and J, are not very large in comparison (1.5, 2.3, 2.5, or 3.1 days compared 
to strategy B), with extra costs of $400, $900, $1,100, or $6,600 compared to strategy 
B. Compared to B, strategy J costs over $778,000 for an added QALY. The large cost 
difference is explained by the early accumulation of costs and discounting beginning 
at age 20. Under realistic monetary constraints, we must consider this large added 
expense when cheaper but still effective strategies exist. This issue is debatable for 
ethical reasons and depends on how much society is willing to pay to save an additional 
year of quality-adjusted life. 
Our model does not make any assumptions on the efficacy of clinical breast exam 
on mortality reduction, but relies on estimates of its sensitivity and specificity. The 
role of clinical breast exam in combination with mammography depends on these 
estimates. The sensitivity analyses showed that higher specificity for clinical breast 
exam leads to lower patient recall rates, which decreases unnecessary work-ups and 
biopsies. However, the lower sensitivity of clinical breast exam increases the false-
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negative rate and delays diagnosis. The performance of screening exams affects the 
timing of diagnosis, recall rate, and intensity of treatment, which all affect overall 
costs and survival. The choice of survival model also has significant impact on the 
results. In a survival model where small changes in tumor size or nodal status have 
little effect on survival, differences in years gained due to screening may be small. 
Regardless of these changes in model assumptions, only two strategies remained more 
effective for a lower cost per QALY saved compared to the alternatives: 1) B: biennial 
mammography and clinical breast exam in alternating years from ages 40-79, and 2) 
J: the most expensive strategy of screening beginning at age 20. 
There are several limitations to our study. First, we considered average medical 
costs as constants and did not take into account the variation across institutions. 
However, we believe our cost inputs are sufficient for this comparative analysis. Sec-
ond, the surgery pattern used may not represent the general population. However, 
it has been shown that long-term costs for mastectomy and BCS are not notably 
different[70]. Third, the treatment options do not include recent changes such as 
third-generation endocrine therapies and axillary or sentinel lymph node dissection, 
because these treatment patterns for the general population were not available in the 
literature. This study also excluded the detection of ductal carcinoma in-situ cases 
which may lead to overdiagnosis, and repeat mammography within six months after 
recall, the relevance of which has recently received attention. Other screening and 
treatment options may be included in a future analysis. 
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While we considered quality-of-life adjustments due to treatments, our analysis 
did not account for physical and emotional effects of screening, unnecessary work-
ups, or biopsies. It is difficult to assign monetary values to such effects. Finally, our 
simulation model assumed full compliance of participants in a screening and treatment 
plan, which allowed us to evaluate the potential effectiveness of a screening program. 
In summary, several alternative cost-effective strategies were found to be more 
efficient than the recommended guidelines, or to have lower costs with minimal loss 
of benefit. In place of current recommendations, biennial mammography and clini-
cal breast exam in alternating years from ages 40-79 was the cheapest cost-effective 
alternative. If enough funds are available to add annual clinical breast exams to a 
screening program, the next cost-effective alternative is to offer biennial mammog-
raphy and annual clinical breast exam from ages 40-79. Breast cancer screening 
strategies with lower costs and benefits comparable to those currently recommended 
should be considered for implementation in practice and for future guidelines. 
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Chapter 3 
Microsimulation Model: High Risk Cohort 
3.1 Background 
The average lifetime risk of breast cancer for a woman in the United States is one 
in seven[77]. However, women who have a strong family history of breast or ovarian 
cancer, cancer-predisposing BRCA mutations, or other clinical indicators including 
Hodgkin disease may have an increased-risk. Some changes to normal screening guide-
lines that may benefit this subset of high-risk women are more frequent examinations, 
or earlier starting ages of examination such as age 30[78]. Due to the higher breast 
density of women at younger ages, mammography may not be as effective at an earlier 
age of screening. Recently the American Cancer Society developed recommendations 
for women at higher risk of breast cancer [79] to receive magnetic resonance imaging, 
or MRI, in addition to mammography. However, there is no consensus on the starting 
age or frequency of MRI. 
While MRI has been found to have a higher sensitivity than mammography, re-
ports of its specificity have been lower[80, 81, 82, 83] in high-risk women, resulting in 
more recalls and biopsies. In addition, MRI is expensive and its administration and 
interpretation requires more highly trained personnel. The potential survival benefit 
that the addition of MRI may provide must be weighed against its costs and higher 
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false-positive rate, which may lead to unnecessary procedures. 
The literature for cost-effectiveness studies focusing on women of increased-risk 
for breast cancer is limited. In one simulation study, the cost-effectiveness of adding 
MRI to mammography screening for BRCA1 or BRCA2 carriers of different age 
groups was evaluated[46]. The authors found that the cost-effectiveness of adding 
MRI to mammography screening varied by age and was better in BRCAl carriers. 
Another observational study, conducted in the UK[84], also found that MRI might 
be cost-effective in high-risk women, especially in BRCAl and BRCA2 carriers. 
In the present study we conduct a cost-effectiveness analysis on a defined cohort 
of women with high-risk for breast cancer using simulation. We assess the cost-
effectiveness of 28 screening strategies of different combinations of mammography and 
clinical breast exam, with or without MRI, with different starting ages and intervals 
between exams (Table 3.1). Included in these strategies are the current recommended 
guidelines for the general population and the cheapest cost-effective alternative for the 
general population. While many of the modeling assumptions in the microsimulation 
model are identical to those from Chapter 2, some changes were necessary in order to 
account for the differences in age-specific incidence, exam sensitivity and specificity, 
and tumor characteristics that are specific to women at higher risk for breast cancer. 
The details of the model are described below. 
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Model 
Components 
Natural History-
Screening Impacts 
Costs Related to 
Screening, Workup, 
and Treatment 
Indirect Costs 
Survival Models 
Data Inputs 
Age-Specific Incidence* 
Age-Specific Pre-clinical Transition* 
Sojourn Time Distributions* 
Tumor Growth Distributions 
Mammography Sensitivity (by age and tumor size)* 
Mammography Specificity (by age)* 
Clinical Breast Exam Sensitivity, Specificity* 
Magnetic Resonance Imaging Sensitivity, Specificity* 
Diagnostic Mammography Sensitivity, Specificity 
Mammography and Clinical Breast Exam 
Magnetic Resonance Imaging* 
Diagnostic Mammography 
Breast Biopsy 
Treatment by Stage 
Lost Productive Time (lost wages) 
By Age, Tumor Size, Nodal Status at Diagnosis, 
ER status, and Treatment 
Competing Risks by Age 
Quality of Life Adjustments by Treatment 
References 
[85] 
[6, 39] 
[86, 40] 
[41] 
[80] 
[80] 
[80] 
[80] 
[45] 
[46, 47] 
[46] 
[46] 
[46] 
[27] 
[48] 
[6, 49, 50, 51] 
[52] 
[53] 
[6, 54] 
*=..New or adjusted data inputs. 
Table 3.2 : Model components and data inputs for high-risk analysis. 
3.2 Model and Data Inputs 
Certain factors associated with the level of breast cancer risk must be modified from 
the original average-risk cohort analysis in Chapter 2 to reflect the screening and 
tumor characteristics of women with a high-risk for breast cancer. These factors 
include the age-specific incidence, mean sojourn time or tumor growth rate, and 
the sensitivity and specificity of mammography, clinical breast exam, and MRI. We 
describe each of these new factors below, with specific data inputs and references 
found in Table 3.2. 
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3.2.1 Age-Specific Incidence 
Because age-specific incidence estimates among high-risk women are not readily avail-
able, we estimated these values based on existing breast cancer risk assessment tools. 
There are several breast cancer risk assessment tools that have been developed, includ-
ing the Gail[87], Claus[88], Tyrer[89], and BRCAPRO[90, 91, 92] models. Contrary 
to the others, the Gail model uses both hereditary and non-hereditary risk factors, 
and does not directly incorporate genotype information. The other models have an 
emphasis on genetic risk factors or require substantial pedigree information. Because 
our study does not focus on genetic risk, but rather a general increase in risk due to 
both genetic and non-genetic factors, we chose to use the Gail model in our analysis. 
We used the Gail model as a template to obtain age-specific risk and thus age-
specific incidence values, assuming certain medical, reproductive, and family history 
risk factors of age at menarche, age at first live birth, number of previous biopsies, 
and number of first-degree relatives with breast cancer. Using an online breast cancer 
risk assessment tool from the NGI based on the Gail model[85], we obtained 5-year 
and lifetime (up to age 90) risks assuming the following characteristics: 
• Age at menarche: 7-11 
• Age at first live birth: > 30 
• Number of previous biopsies: > 1 
• Number of first-degree relatives with breast cancer: > 1 
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These selected characteristics will yield a a more elevated risk for breast cancer than if 
milder characteristics (such as higher age of menarche or no previous live births) were 
chosen. The resulting lifetime risks ranged between about 25% to 50% for women 
ages 40 to 80. According to the ACS, annual MM is recommended if a woman's 
lifetime risk is about 20-25% or more, but there is insufficient evidence to recommend 
MRI screening in women with lifetime risk of less than 20% [79]. 
For each group we calculated age-specific incidence rates from the computed haz-
ard rates, where the incidence values ranged from about 0.6% to 2.5% for ages 30-79. 
Compared to the age-specific incidence rates used in Chapter 2 for the general popu-
lation, the resulting age-specific incidence rates were about 10 times higher than the 
original values for our so-called high-risk group. 
3.2.2 Tumor Characteristics 
Women with increased-risk for breast cancer may experience faster tumor growth. 
Because of the likely shorter duration of the time spent in the preclinical state, we 
used shorter mean sojourn times of 1.0 years for women < 50 and 1.9 years for women 
> 50 [86]. This shorter preclinical sojourn time accounts for the faster tumor growth. 
3.2.3 Screening Impacts 
The sensitivity and specificity of mammography and clinical breast exam differ be-
tween the general population and women with high-risk for breast cancer. Sensitivities 
have been shown to be lower in the subset of high-risk women, and specificities have 
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been shown to be higher for both screening modalities [80]. The lower sensitivities 
may be partially explained by the higher breast density of high-risk women who re-
ceive screening at a younger age, which contributes to difficult interpretation of the 
exams. Again, we assume age- and tumor size- specific sensitivity (/?i(40,1) = 0.40, 
A (60,1) = 0.60, ft (40,0.05) = 0.05) and age-specific specificity (<Ji(40) = 0.95, 
5j(60) = 0.98) for mammography, and constant sensitivity (/32 = 0.178) and speci-
ficity (82 = 0.981) for clinical breast exam reported in Kriege et al. (2004) [80]. 
Uncertainty is accounted for using a beta distribution for each sensitivity, where the 
parameters of the distribution are determined in a manner identical to that used for 
the general population in Chapter 2, where the effective sample sizes are SMM = 30 
and SCBE = 40. 
For MRI, we assume the specificity is constant (83 =. 0.90), and the sensitivity 
is tumor-size specific, where the sensitivity is higher than that of mammography at 
the same tumor size (&(0.05) = 0.25, /33(1) = 0.71) [80]. As before, we also add 
uncertainty for this exam, using SMRI = 30. It is assumed that all three examination 
modalities work independently of each other in detecting breast cancer. A logit model 
is again used to model the age or tumor-size dependencies. 
3.2.4 Costs 
We have now added the cost of $996 for bilateral MRI[46] (2004 dollars), while all 
other costs remain the same as in Chapter 2. 
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3.2.5 Sensitivity Analysis 
To assess how sensitive our model assumptions are to changes in the sensitivities of 
mammography and MRI, we used higher sensitivity estimates for mammography or 
clinical breast exam, according to the general population, using the same estimates 
from Chapter 2 [42, 44]. We also used milder characteristics from the GAIL model to 
generate lower lifetime risks ranging from about 7% to 17% and age-specific incidence 
values that ranged from about 0.06% to 0.8% for ages 30-79, which may still represent 
a cohort of higher risk relative to the general population (about 2.5 times higher than 
the original incidence values used for the general population in Chapter 2). 
3.3 Results 
The results in Table 3.3 show that every evaluated screening strategy extended life 
expectancy compared to no screening, but only a few strategies were more cost-
effective compared to the alternatives. Other strategies were eliminated by simple or 
extended dominance. 
For the high-risk cohort, strategies A, D, I, N, and b had lower costs per QALY 
saved than the alternatives. Strategies A, D, and I gave mammography alone every 
2, 1, and 0.5 years, respectively, beginning at age 40. Strategy A saved about 5 days 
of life compared to no screening, costing $45,600 per QALY saved. Strategy D gained 
3 days compared to strategy A, and strategy I gained 4 days compared to strategy 
D, costing an additional $99,300 per QALY compared to strategy D. Strategy N, 
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which gave mammography and clinical breast exam every six months from ages 30-
79, cost an additional $228,700 per QALY saved compared to strategy I. Strategy b 
gave mammography and clinical breast exam every six months with the addition of 
MRI every year. Adding annual MRI resulted in 3 days gained compared to strategy 
N. This strategy which includes annual MRI is very expensive, costing more than $2 
million to save one QALY compared to strategy N, the next cheapest cost-effective 
alternative. 
The tradeoff plot for the high-risk cohort is found in Figure 3.1, corresponding 
to Table 3.3. Note that the strategies appear to be clustered into three groups, 
depending on whether or not the strategy uses MRI, and whether MRI is annual or 
biennial. Overall the dominated strategies fall below the line connecting the non-
dominated alternatives. It is clear from both plots that there is a large tradeoff in 
costs to achieve a small gain in survival benefit as the efficiency frontier is followed 
upward. 
We display the standard errors of the cost difference and gain in QALYs compared 
to no screening in Figure 3.2 (for total cost difference less than $7,000), Figure 3.3 
(for total cost difference between $7,000 and $17,000), and Figure 3.4 (for total cost 
difference greater than $17,000). Based on the standard errors, it is clear that strategy 
V, which offers mammography and clinical breast exam every six months and MRI 
every two years from ages 30-79 may still be an efficient strategy and should not be 
ruled out from the efficiency frontier. All other strategies appear to fall significantly 
42 
Table 3.3 : Results of cost-effectiveness analysis in a high-risk cohort. Costs and 
QALYs are discounted at 3%. Strategies that are dominated or eliminated through 
extended dominance are indicated with '—'. 
Strat 
* 
A 
B 
C 
D 
E 
G 
F 
H 
I 
J 
K 
L 
M 
N 
0 
P 
Q 
R 
S 
T 
U 
V 
W 
X 
Y 
Z 
a 
b 
MM 
intv(age) 
— 
2(40-79) 
2(40-79) 
2(40-79) 
1(40-79) 
2(30-79) 
2(30-79) 
1(40-79) 
1(40-79) 
0.5(40-79) 
1(30-79) 
2(30-79) 
0.5(40-79) 
1(30-79) 
0.5(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
0.5(30-79) 
2(30-79) 
1(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
0.5(30-79) 
CBE 
intv(age) 
— 
2(41-79) 
2(40-79) 
2(30-79) 
1(30-79) 
1(40-79) 
3(20-39), 
1(40-79) 
1(30-79) 
0.5(30-79) 
0.5(40-79) 
0.5(30-79) 
0.5(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
1(30-79) 
0.5(30-79) 
0.5(30-79) 
2(30-79) 
0.5(30-79) 
1(30-79) 
1(30-79) 
1(30-79) 
0.5(30-79) 
0.5(30-79) 
0.5(30-79) 
MRI 
intv(age) 
— 
2(31-79) 
2(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
1(30.5-79) 
1(30-79) 
1(30-79) 
1(30-79) 
1(30-79) 
Total 
Cost ($) 
14,700 
15,300 
15,600 
15,600 
15,800 
16,000 
16,400 
16,400 
16,500 
16,800 
17,100 
17,200 
17,900 
18,000 
19,500 
24,500 
24,900 
25,300 
26,000 
26,100 
26,900 
27,200 
28,400 
33,400 
34,500 
34,600 
34,700 
35,500 
37,000 
QALYs Increm. 
(years) QALYs 
gained 
27.2381 
27.2514 0.0134 
27.2543 — 
27.2535 — 
27.2585 0.0071 
27.2559 — 
27.2597 — 
27.2617 — 
27.2633 — 
27.2684 0.0099 
27.2669 — 
27.2663 — 
27.2718 — 
27.2718 — 
27.2801 0.0118 
27.2696 — 
27.2645 — 
27.2668 — 
27.2729 — 
27.2716 — 
27.2767 — 
27.2688 — 
27.2840 — 
27.2763 — 
27.2834 — 
27.2775 — 
27.2794 — 
27.2814 — 
27.2881 0.0080 
ICER 
45,600 
— 
— 
71,200 
— 
— 
— 
99,300 
— 
— 
— 
— 
228,700 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
2,195,800 
MM=Mammography; CBE=Clinical breast exam; MRI=Magnetic Resonance Imaging; intv=time 
interval between examinations (in years); age=age range; Increm=incremental 
Total Cost: Mean total cost per woman in the complete cohort, rounded to the nearest $100 
QALYs: Mean total expected quality-adjusted life years per woman from age 20 
ICER: Incremental cost-effectiveness ratio (incremental cost/incremental QALYs gained compared 
to next least-expensive strategy) 
43 
15000 20000 25000 
Total cost ($) 
30000 35000 
Figure 3.1 : Tradeoff plot for the high-risk cohort. X-axis is mean total cost in U.S. 
dollars. Y-axis is mean quality-adjusted life-years. Dominated strategies fall below 
the line of efficiency connecting the non-dominated alternatives (A,D,I,N,b). 
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Figure 3.2 : Tradeoff plot of gains in QALY and difference in cost compared to 
no screening for the high-risk cohort. X-axis is mean total cost difference in U.S. 
dollars, ranging from $0 to $7,000. Y-axis is mean gain in quality-adjusted life-years. 
Standard error bars for the mean gain in QALYs (vertical) and mean total cost 
difference (horizontal endpoints) compared to no screening are shown. 
45 
in o 
L_ 
CD 
>^; 
D) 
C 
"c 
a) CD i _ 
o CO 
o 
c 
o 
*^  T3 
CD 
i -
CO 
Q. 
E 
o 
o CO 
>-
_1 
< 
O 
CD 
o 
-* q 
o 
CO 
o d 
CM 
o 
c> 
o 
d 
8 -J 
fT 
} 0 fU 
«Q 
IP 
8000 10000 12000 14000 16000 
Total cost difference compared to no screening ($) 
Figure 3.3 : Tradeoff plot of gains in QALY and difference in cost compared to no 
screening for the high-risk cohort. X-axis is mean total cost difference in U.S. dollars, 
ranging from $7,000 to $17,000. Y-axis is mean gain in quality-adjusted life-years. 
Standard error bars for the mean gain in QALYs (vertical) and mean total cost 
difference (horizontal endpoints) compared to no screening are shown. 
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Figure 3.4 : Tradeoff plot of gains in QALY and difference in cost compared to 
no screening for the high-risk cohort. X-axis is mean total cost difference in U.S. 
dollars, from $17,000 and greater. Y-axis is mean gain in quality-adjusted life-years. 
Standard error bars for the mean gain in QALYs (vertical) and mean total cost 
difference (horizontal endpoints) compared to no screening are shown. 
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below the line of efficiency. 
3.3.1 Sensitivity Analysis 
When higher sensitivity values according to the general population are used for clinical 
breast exam, the results are different. The gain in survival for the strategies is higher 
compared to the original analysis using lower sensitivity, which may be explained 
by the clinical breast exam's increased effectiveness. The nondominated strategies 
become strategies B, G, K, N, V, and b in the high-risk cohort. Strategies B, G, and K 
reflect strategies which were not cost-effective when the clinical breast exam sensitivity 
was lower. For instance, strategy B, which offers mammography and clinical breast 
exam in alternating years from ages 40-79 becomes cost-effective while strategy A, 
which gives mammography alone biennially from ages 40-79 becomes dominated. 
Thus the sensitivity of clinical breast exam has a significant impact on the cost-
effectiveness of the strategies. 
When higher sensitivity values for mammography are used, there is less of an 
impact on the results. Although the survival gain is slightly higher, the overall results 
are not that different. We found that the strategies with a lower cost per QALY saved 
than the alternatives were the same, except strategy V became cost-effective when 
it was not in the original analysis, which used lower sensitivity for mammography. 
For this strategy, the higher sensitivity of mammography may make up for its less 
frequent MRI, making it more efficient than before. However, taking the standard 
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error into account, this strategy was essentially already an efficient strategy to begin 
with. The minimal impact of increasing mammography sensitivity may be partly 
attributed to the assumption that its sensitivity is always higher than that of clinical 
breast exam and smaller than that of MRI. Increasing its sensitivity within these 
limits does not really affect the order of effectiveness for the strategies of interest. 
By using relatively lower incidence values of 0.06% to 0.8% for ages 30-79, the 
overall results are essentially identical to the analysis using higher incidence values. 
The expected total costs are lower, which may be due to less intense treatments, but 
otherwise the strategies with a lower cost per QALY gained were strategies A, D, I, N, 
V, and b. A simultaneous change in tumor characteristics together with the change 
in incidence may lead to a significant impact on the cost-effectiveness results. 
3.4 Discussion 
This study extends the analysis in Chapter 2 to a cohort of high-risk women for breast 
cancer. We account for differences in age-specific breast cancer incidence according to 
pre-specified characteristics under the GAIL model, tumor characteristics, and exam 
sensitivity and specificity among this population, and include a recently recommended 
screening exam in some of the studied strategies: magnetic resonance imaging. All 
costs due to screening, work-up, biopsies due to true-or false-positive examinations, 
and treatments are included. 
Mammography alone every one or two years beginning at age 40, which are two 
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Table 3.4 : Results of sensitivity analysis in a high-risk cohort using a higher sensitiv-
ity value for clinical breast exam. Costs and QALYs are discounted at 3%. Strategies 
that are dominated or eliminated through extended dominance are indicated with 
'—'. Dominated strategies are indicated with '—'. 
Strat 
* 
A 
B 
C 
D 
E 
G 
F 
H 
I 
J 
K 
L 
M 
N 
0 
P 
Q 
R 
S 
T 
U 
V 
W 
X 
Y 
Z 
a 
b 
MM 
intv(age) 
— 
2(40-79) 
2(40-79) 
2(40-79) 
1(40-79) 
2(30-79) 
2(30-79) 
1(40-79) 
1(40-79) 
0.5(40-79) 
1(30-79) 
2(30-79) 
0.5(40-79) 
1(30-79) 
0.5(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
0.5(30-79) 
2(30-79) 
1(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
0.5(30-79) 
CBE 
intv(age) 
— 
2(41-79) 
2(40-79) 
2(30-79) 
1(30-79) 
1(40-79) 
3(20-39), 
1(40-79) 
1(30-79) 
0.5(30-79) 
0.5(40-79) 
0.5(30-79) 
0.5(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
1(30-79) 
0.5(30-79) 
0.5(30-79) 
2(30-79) 
0.5(30-79) 
1(30-79) 
1(30-79) 
1(30-79) 
0.5(30-79) 
0.5(30-79) 
0.5(30-79) 
MRI 
intv(age) 
— 
2(31-79) 
2(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
1(30.5-79) 
1(30-79) 
1(30-79) 
1(30-79) 
1(30-79) 
Total 
Cost ($) 
14,700 
15,300 
15,600 
15,600 
15,800 
15,900 
16,300 
16,400 
16,500 
16,800 
17,100 
17,200 
17,900 
17,900 
19,500 
24,500 
24,900 
25,300 
26,000 
26,100 
26,900 
27,300 
28,400 
33,400 
34,400 
34,600 
34,700 
35,400 
37,000 
QALYs Increm. 
(years) QALYs 
gained 
27.2380 
27.2514 — 
27.2598 0.0219 
27.2568 — 
27.2590 — 
27.2618 — 
27.2720 0.0122 
27.2678 — 
27.2716 — 
27.2678 — 
27.2749 — 
27.2853 0.0133 
27.2791 — 
27.2870 — 
27.2904 0.0051 
27.2732 — 
27.2711 — 
27.2753 — 
27.2782 — 
27.2867 — 
27.2892 — 
27.2752 — 
27.2927 0.0022 
27.2810 — 
27.2892 — 
27.2808 — 
27.2914 — 
27.2911 — 
27.2939 0.0012 
ICER 
— 
41,200 
— 
— 
— 
59,600 
— 
— 
— 
62,100 
— 
— 
447,700 
— 
— 
— 
— 
— 
— 
— 
3,994,000 
— 
— 
— 
— 
— 
6,928,600 
MM=Mammography; CBE=Clinical breast exam; MRI=Magnetic Resonance Imaging; intv=time 
interval between examinations (in years); age=age range; Increm=incremental 
Total Cost: Mean total cost per woman in the complete cohort, rounded to the nearest $100 
QALYs: Mean total expected quality-adjusted life years per woman from age 20 
ICER: Incremental cost-effectiveness ratio (incremental cost/incremental QALYs gained compared 
to next least-expensive strategy) 
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Table 3.5 : Results of sensitivity analysis in a high-risk cohort using higher sensitivity 
values for mammography. Costs and QALYs are discounted at 3%. Strategies that 
are dominated or eliminated through extended dominance are indicated with '—'. 
Strat 
* 
A 
B 
C 
D 
E 
G 
F 
H 
I 
J 
K 
L 
M 
N 
0 
P 
Q 
R 
S 
T 
U 
V 
w 
X 
Y 
Z 
a 
b 
MM 
intv(age) 
— 
2(40-79) 
2(40-79) 
2(40-79) 
1(40-79) 
2(30-79) 
2(30-79) 
1(40-79) 
1(40-79) 
0.5(40-79) 
1(30-79) 
2(30-79) 
0.5(40-79) 
1(30-79) 
0.5(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
0.5(30-79) 
2(30-79) 
1(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
0.5(30-79) 
CBE 
intv(age) 
— 
2(41-79) 
2(40-79) 
2(30-79) 
1(30-79) 
1(40-79) 
3(20-39), 
1(40-79) 
1(30-79) 
0.5(30-79) 
0.5(40-79) 
0.5(30-79) 
0.5(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
1(30-79) 
0.5(30-79) 
0.5(30-79) 
2(30-79) 
0.5(30-79) 
1(30-79) 
1(30-79) 
1(30-79) 
0.5(30-79) 
0.5(30-79) 
0.5(30-79) 
MRI 
intv(age) 
— 
2(31-79) 
2(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
1(30.5-79) 
1(30-79) 
1(30-79) 
1(30-79) 
1(30-79) 
Total 
Cost ($) 
14,700 
15,300 
15,600 
15,600 
15,800 
15,900 
16,400 
16,400 
16,500 
16,800 
17,100 
17,200 
17,900 
18,000 
19,500 
24,500 
24,900 
25,300 
26,000 
26,100 
26,900 
27,300 
28,400 
33,400 
34,500 
34,600 
34,700 
35,500 
37,000 
QALYs Increm. 
(years) QALYs 
gained 
27.2385 
27.2547 0.0162 
27.2561 — 
27.2574 — 
27.2646 0.0099 
27.2598 — 
27.2639 — 
27.2661 — 
27.2673 — 
27.2742 0.0096 
27.2726 — 
27.2683 — 
27.2773 — 
27.2770 — 
27.2866 0.0124 
27.2720 — 
27.2668 — 
27.2670 — 
27.2763 — 
27.2727 — 
27.2798 — 
27.2701 — 
27.2899 0.0033 
27.2769 — 
27.2871 — 
27.2794 — 
27.2802 — 
27.2829 — 
27.2913 0.0014 
ICER 
39,400 
— 
— 
49,100 
— 
— 
— 
104,900 
— 
— 
— 
— 
214,200 
— 
— 
— 
— 
— 
— 
— 
2,664,100 
— 
— 
— 
— 
— 
6,008,300 
MM=Mammography; CBE=Clinical breast exam; MRI=Magnetic Resonance Imaging; intv=time 
interval between examinations (in years); age=age range; Increm=incremental 
Total Cost: Mean total cost per woman in the complete cohort, rounded to the nearest $100 
QALYs: Mean total expected quality-adjusted life years per woman from age 20 
ICER: Incremental cost-effectiveness ratio (incremental cost/incremental QALYs gained compared 
to next least-expensive strategy) 
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Table 3.6 : Results of sensitivity analysis in a high-risk cohort where the age-specific 
incidence rates are lower than the original analysis. Costs and QALYs are discounted 
at 3%. Strategies that are dominated or eliminated through extended dominance are 
indicated with '—'. 
Strat 
* 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
K 
L 
M 
N 
0 
P 
Q 
R 
S 
T 
U 
V 
W 
X 
Y 
Z 
a 
b 
MM 
intv(age) 
— 
2(40-79) 
2(40-79) 
2(40-79) 
1(40-79) 
2(30-79) 
1(40-79) 
2(30-79) 
1(40-79) 
0.5(40-79) 
1(30-79) 
2(30-79) 
0.5(40-79) 
1(30-79) 
0.5(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
0.5(30-79) 
2(30-79) 
1(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
0.5(30-79) 
CBE 
intv(age) 
— 
2(41-79) 
2(40-79) 
2(30-79) 
1(40-79) 
1(30-79) 
3(20-39), 
1(40-79) 
1(30-79) 
0.5(30-79) 
0.5(40-79) 
0.5(30-79) 
0.5(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
1(30-79) 
0.5(30-79) 
0.5(30-79) 
2(30-79) 
0.5(30-79) 
1(30-79) 
1(30-79) 
1(30-79) 
0.5(30-79) 
0.5(30-79) 
0.5(30-79) 
MRI 
intv(age) 
— 
2(31-79) 
2(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
2(30-79) 
1(30-79) 
2(30-79) 
1(30-79) 
1(30.5-79) 
1(30-79) 
1(30-79) 
1(30-79) 
1(30-79) 
Total 
Cost ($) 
13,100 
13,700 
14,000 
14,000 
14,200 
14,400 
14,800 
14,800 
15,000 
15,200 
15,600 
15,700 
16,300 
16,400 
18,000 
23,100 
23,400 
23,800 
24,600 
24,700 
25,500 
25,800 
27,000 
32,100 
33,100 
33,300 
33,400 
34,100 
35,700 
QALYs Increm. 
(years) QALYs 
gained 
27.3204 
27.3340 0.0136 
27.3373 — 
27.3361 — 
27.3419 0.0079 
27.3387 — 
27.3453 — 
27.3412 — 
27.3458 — 
27.3519 0.0100 
27.3487 — 
27.3475 
27.3550 — 
27.3529 — 
27.3613 0.0093 
27.3509 — 
27.3461 — 
27.3473 — 
27.3533 — 
27.3521 — 
27.3577 — 
27.3484 — 
27.3651 0.0038 
27.3563 — 
27.3635 — 
27.3585 — 
27.3601 — 
27.3619 — 
27.3676 0.0025 
ICER 
44,400 
— 
— 
63,800 
— 
— 
— 
" 
98,400 
— 
— 
— 
— 
298,600 
— 
— 
— 
— 
— 
— 
— 
2,346,200 
— 
— 
— 
— 
— 
3,487,800 
MM=Mammography; CBE=Clinical breast exam; MRI=Magnetic Resonance Imaging; intv=time 
interval between examinations (in years); age=age range; Increm=incremental 
Total Cost: Mean total cost per woman in the complete cohort, rounded to the nearest $100 
QALYs: Mean total expected quality-adjusted life years per woman from age 20 
ICER: Incremental cost-effectiveness ratio (incremental cost/incremental QALYs gained compared 
to next least-expensive strategy) 
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strategies that are currently recommended guidelines for the general population, are 
cost-effective strategies compared to the alternatives in the high-risk population. In-
creasing the frequency to every six months is also cost-effective with an increased 
survival benefit but with a higher cost. For a program which includes mammography 
and clinical breast exam, giving these exams every six months beginning at age 30 is 
more life-saving than the strategies above, but quite expensive. Even more expensive, 
but more effective, is to add MRI every 1 or 2 years. 
Thus it appears that even for a population with higher risk for breast cancer, 
the cheapest but still effective screening strategies among those considered are the 
ones that give mammography alone. For an added expense and only 3-4 days benefit 
compared to mammography alone, mammography and clinical breast exam may be 
combined every six months. The addition of MRI to the screening programs is more 
life-saving but much more expensive, and the high added expense must be considered 
when the gain in benefit is small. 
If clinical breast exam had better performance among women of higher risk, more 
strategies combining mammography and clinical breast exam would be cost-effective. 
The sensitivity of this test makes a significant impact on which strategies are cost-
effective. It is thus crucial that appropriate sensitivity estimates for clinical breast 
exam are used in such an analysis, and that the results are interpreted carefully, 
according to which estimates are assumed. On the other hand, given that the sensi-
tivity of mammography is always larger than the sensitivity of clinical breast exam 
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and smaller than the sensitivity of MM, any changes in the sensitivity of mammog-
raphy within this boundary has little effect on the overall cost-effectiveness of the 
strategies. 
While the American Cancer Society has issued recommendations to add MRI to 
mammography for women with increased-risk for breast cancer, our analysis indicates 
that adding periodic MRI to mammography screening is very expensive and the gain 
in survival is relatively small. Giving mammography with or without clinical breast 
exam is much cheaper and sacrifices only a small gain in benefit. It is possible that 
improvements in the administration and interpretation of MRI may make it a more 
effective screening exam, but because of its high expense, it may not be worth it to 
recommend regular periodic screening with MRI. 
The limitations mentioned in Chapter 2 still apply to this analysis. In addition, 
data on women of increased breast cancer risk are currently limited in the literature. 
While clinical trials for MRI in a high-risk group for breast cancer are currently 
underway, there are no large randomized, controlled clinical trials that have been 
completed assessing the use of MRI as a mode of screening for healthy women at high-
risk for breast cancer. We thus relied on the information that was readily available 
in the literature for use in our data inputs and models. If more updated information 
becomes available, it may be substituted into the models. 
Overall, we report our findings from a societal perspective. Among an increased-
risk population, a screening program which gives mammography alone beginning at 
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age 40 is the cheapest cost-effective option, and spending the money to add clinical 
breast exam or MRI does not add much benefit. However, if cost is not an issue, then 
the more ethically acceptable choice from a patient's perspective would be to give 
mammography and clinical breast exam every six months beginning at age 30, with 
MRI every 1 or 2 years. While it may be beneficial to give women of higher breast 
cancer risk earlier or more frequent exams with MRI, it is expensive and the costs 
required for the small benefit must be carefully considered. 
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Chapter 4 
Utility Function 
4.1 Background 
While a simulation model has its advantages of modeling disease history and assessing 
the benefits and costs directly for a given set of different screening programs (a local 
optimum) simultaneously, a mathematical model can be a useful tool for searching for 
an optimal screening schedule (a global optimum) but under potentially more strict 
model assumptions. 
Despite broad attention to modeling the general screening process, less attention 
has been given to the optimization of examination schedules for screening exami-
nations using mathematical models. Optimal examination schedules may be deter-
mined by factors such as the initial age to begin a screening examination program, 
the intervals between subsequent examinations, and the number of examinations. 
Works by Parmigiani[93], Tsodikov and Yakovlev[94], Shahani and Crease[95], Lee 
and Zelen[96], and Zelen[59] are examples of efforts to address optimal examination 
schedules in the setting of early detection. We give brief and general reviews of these 
approaches, then present our proposed mathematical model under two frameworks. 
Parmigiani (1993) took a decision theoretic approach, where the decision space 
consists of all possible sequences of examination times. Optimal schedules are chosen 
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to minimize the risk R(T), or total expected loss due to an examination schedule 
r, accounting for the expected number of examinations and the expected losses due 
to mortality, morbidity, costs, and other factors associated with the disease. He 
considered the effect of age on the optimal schedule of examinations by modeling age-
specific incidence and age-specific competing risks. Although his formula for finding 
the optimal examination schedule is general enough, he can only solve the problem 
under a few very special cases: 1. when there is only one exam; and 2. under perfect 
exam sensitivity. He concluded that optimal periodic examinations (with a constant 
interval) can be derived only under restrictive assumptions (such as sensitivity=l), 
and non-periodic screening intervals for different age cohorts may maximize benefit 
instead. 
Tsodikov and Yakovlev (1991) addressed the problem of optimal screening with 
non-periodic examinations using a minimum delay time approach and a minimum cost 
approach. In the minimum delay time approach, the number of exams is assumed 
to be fixed, and the problem is to construct the screening schedule given the fixed 
number of exams that maximizes the benefit through minimization of the expected 
delay time. The minimum cost approach was used to find the optimal schedule of 
examinations (and thereby the optimal number of exams) by minimizing the total 
costs due to screening and late detection of the disease. 
Alternatively, Lee and Zelen (1998) considered two different approaches to select 
the optimal screening schedule, specifically with applications to breast cancer. The 
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first was the threshold method which selects examination schedules within a screen-
ing horizon according to a preselected threshold value, such as the probability of 
an individual being in the preclinical state. Examinations are carried out when an 
individual's risk status reaches that threshold. The second approach was schedule 
selection based on schedule sensitivity, defined as the ratio of expected number of 
diagnosed cases to the total expected number of cases. This approach does not give 
a unique solution. The combination of these two methods allows for the evaluation 
of screening schedules based on the tradeoffs between schedule sensitivity and costs. 
Similar to Tsodikov and Yakovlev (1991), Zelen (1993) assumed a fixed cost (or 
number of exams) while maximizing the health benefit. In Zelen's approach, he 
considers a screening horizon [0, T] for a fixed number of examinations at times 
0 = to,ti,...,tn = T and general formulations for probability of detection at screening 
(screening detection) and probability of diagnosis between screening (interval detec-
tion). Instead of minimizing the expected delay time, Zelen's approach seeks to 
maximize a weighted difference between screening and interval detected cases. 
The following general expressions were derived by Zelen for the probability that 
the disease is detected at the ith screening exam when the sensitivity is 0 < (5 < 1 
(Di({3)), and the probability that an individual is incident at age t after i exams 
(Wit)): 
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Do{0) = pP(t0) 
Di(P) = 0<J2(1-P)i'Jpj(tj)Qj(ti-tj)+ [' w{x)Q(ti- x)dx\,i=l, ...,n 
»-i ft 
Ii(P, t) = ] T ( 1 - PY^Pjit^qjit -tj)+ w{x)q{t - x)dx, i = 1,..., n, 
where w(t) is the preclinical transition rate, P(t) is the prevalence of disease at time 
t, q(t) is the probability density function of the sojourn time, and Q(t) is the survival 
function for q(t), and Pi(ti)qi(t) — ft' w(x)q(ti — x + t)dx. 
Using these formulations, Zelen proposed a utility function that represents a 
weighted difference between the probability of screening detection and the proba-
bility of interval detection for a screening program with n + 1 examinations: 
n n 
Un+1 = A^Diffl-BJ^IiiP), 
i=0 t = l - . 
where the weights A and B are non-negative and A > B. The weights may, for 
example, represent the probability of a cure when disease is found through a screening 
examination or an interval case. The idea is to maximize the utility with a screening 
schedule which will yield a large number of screening detections and a smaller number 
of clinical incidence cases between exams. 
The utility function is thus a function of screening sensitivity, disease incidence, 
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and the preclinical sojourn time distribution. In particular, Zelen assumes a stable 
disease model, where transition into the preclinical state H —• P is independent of age. 
The optimal values {U} are then found by maximizing the utility function under these 
assumptions, where the {U} define the optimal spacing of examinations. Although 
the assumption of a stable disease model significantly simplifies the formulations, it 
can be unrealistic for a potentially long screening horizon. 
In the current work, we extend Zelen's approach under the more general assump-
tion of a non-stable disease model by taking into consideration age-dependent pre-
clinical incidence of disease, as well as costs of screening exams and the dollar value 
of benefit. We will explore two frameworks for the utility function given the esti-
mated age-dependent preclinical incidence, screening sensitivity, and sojourn time 
distribution: 
1. Equal Intervals We will derive the optimal number of examinations within a 
specified screening horizon [to, T], with tn = T and assuming that the intervals 
between exams are equal. 
2. Fixed Budget We will derive the optimal ages of examinations within a spec-
ified screening horizon [tp,T], with tn < T, given the number of examinations 
(fixed budget) and allowing the intervals between examinations to be unequal. 
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4.2 Proposed Models 
In each proposed framework, we consider the following general form for the utility 
function which includes a cost deduction: 
U — Value Of Benefit — Cost Of Screening, 
where the Value of Benefit denotes the dollar value of the benefit due to a screening 
program, and Cost of Screening denotes the cost of screening examinations in that 
screening program. Then the goal will be to maximize U, or the value of the benefit 
when costs for screening are deducted. 
Using Zelen's expressions as a template, we present two proposed frameworks 
to find the optimal screening schedule under a non-stable disease model. In both 
frameworks, w(x), the age-dependent transition rate from H —> P is assumed to be a 
continuous function of the form k\x — k0 where ki and k0 are constants, and w(x) — 0 
for x < I s . For instance, for I2- = 20, the transition rate is zero for ages x < 20. 
We assume that ^ < i0- The probability density function for the sojourn time is 
assumed to be exponential with mean /i = j . We present proofs of the existence of a 
solution for both scenarios and some numerical optimization results. 
4.2.1 Framework 1: Equal Intervals 
Although the earlier settings in previous works showed that choosing equal intervals 
may not be optimal unless the exam sensitivity is one[93, 59], it may have practical 
61 
advantages in its convenience and feasibility of enforcement. Under the assumption 
of equal intervals, we present a utility function where the number of exams (n), or 
equivalently the interval between exams (A), in a screening schedule is unknown. The 
n (or A) which maximizes the utility function will define the optimal schedule when 
exams are equally spaced. 
Presentation of Model 
Using Zelen's expressions for £?*(/?) and Ii(p,t), we define the utility function as 
follows: 
U(n) = Value Of Benefit(n) — Cost Of Screening(n) 
•A £ A ( 0 ) - S £/,(/?) -C 2 (n+l ) . 
i=0 i=\ / 
We assume that the Benefit is the difference in cure rates between those found on 
examination compared to interval cases, where A is the probability of a cure when 
disease is found through screening, B is the probability of a cure for an interval case, 
C\ is the average dollar value of survival benefit due to one life cured, and Ci is the 
average cost of a screening exam. We assume a fixed screening horizon of ages [t0, T], 
and assume that n + 1 examinations at times t0, t\> ..., tn = T are equally-spaced at 
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intervals of A = t{ — tj_j. Then the following expressions follow: 
A = l^h 
n 
U = t0 + iA 
= t0 + -(T-to)ti = l,...,n. 
n 
Using these expressions in the utility function, we can find the n* that maximizes 
U(n), and therefore solve for the optimal A*. 
Proof for Existence of Solution 
In the derivations below, we first simplify the problem to eliminate the summations, 
using properties of the geometric series, then use Taylor series expansion to approx-
imate U(n). Note that the term D0(P) is not dependent on n, and may thus be 
excluded in the proof. We begin by rewriting 
om = P\ 5 > - py^PjiWQjiti - h) + fl w(x)Q(u - x)dx 
with expressions for Pj(tj)qj(t) and Pj(tj)Qj(ti — tj). The proof is given under an 
exponential assumption with mean /i = i for the sojourn time distribution. 
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For j = 0, 
Po(to)qo(t) = 
and 
/•to 
/ w(x)q(to — x + t)dx 
Jo 
/•to rto 
/ kix\exp(—X(to — x + t))dx — I ko\exp(—\(to —x+ t))dx 
Jo Jo 
fj,ki exp(-A(t + t0)) + k\(to - /x) exp(-At) 
fcpexp(-At) + A;oexp(-A(to + t)), 
Po{to)Qo(ti -10) = 
/•OO 
/ Po(to)qo{t)dt 
Jti—to 
/•OO 
/ {iik\ exp(- \{ t + to)) + ki (t0 - M) exp(-At) 
Jti—to 
—ko exp(—At) + ko exp(—A(to + t))) dt 
H2k\ exp(-Atj) + kin(t0 - n) exp(-A(t; - t0)) 
- fikoexp(-X(t{ - to)) + /i/coexp(—Atj). 
For j > 0, 
fh 
•Pj(tj)qj(t) = / w(x)q(tj - x + t)dx 
Jtj-i 
ptj rtj 
= / kix\exp(—X(tj — x + t))dx — / koXexp(—X(tj — x+ t))dx, 
Jtj-i Jtj-i 
and 
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Also, 
nOO 
PjWQjiU-tj) = / Pj{tj)qj{t)dt 
J ti—tj 
r°° rh 
= I kyxXexp(-X(tj+ t))exp(Xx)dxdt 
Jti—tj **tj—\ 
r°° rh 
— I I fcoAexp(—X(tj + t)) exp(Xx)dxdt 
•J t% — tj J tj — \ 
f°° fli 
= I koexp(~X(tj+ t))dt I Xexp(Xx)dx 
«/ ti — tj *J tj — 1 
r°° ft] 
— / k\exp(—X(tj + t))dt / Xxexp(Xx)dx 
•/ I j — tj v tj — \ 
= kifiexp(-Xti) ((tj — n)exp(Aij) — (tj-i — /u)exp(At,_i)) 
— &o/xexp(—Xt{)(exp(Xtj) — exp(Xtj-i)). 
rU rU rU 
I w(x)Q(ti — x)dx — \ kixexp(—X(ti — x))dx — / ko exp(—X(U — x))dx 
Jti-i Jti~\ y*i- i 
= fcijuexp(-Aij) ((U - (j,) exp(Aij) - (*»_i - /i) exp(Ati_i)) 
- fco/i + ko/j,exp(-X(ti - U-i)). 
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Then using the above expressions, we rewrite Di(f3): 
22(1 - py-iPjit^QjiU - tj) + / w(x)Q(U - x)da 
j=0 , ' t <- i 
Di(J3) = 0{ 
[3 0 
= /?{(! - p)\n2kx exp(-XU) + klfi(t0 - fi) exp(-A(ti - t0)) 
- nk0exp(-\(ti - t0)) + /ifc0exp(-Atj)) 
i - 1 
+ J ^ ( l - /3)i_J'{A;1/iexp(-Aii)((«j - M) exp(Atj) - (tj_i - fi) exp(Afy-i)) 
- fcoMexP(—Ati)(exp(Atj-) — exp(Atj_i))} 
+ fci^exp(-Aii)((tj - //) exp(Atj) - (tj-i - A*) exp(Ati_i)) 
- fco/u. + fco//exp(—A(tj - *i-i))} 
0kitiexp(-Xti){{l ~ PVn + (1 - PY(to - n)exp(Xto) 
+ (1 - f3)i-1((t1 - n) exp(Ati) - (to - fi) exp(Afo)) 
+ (1 - ^)i-2((f2 - /i) exp(Afc) -'-(ti - fi) exp(Atx)) + . . . 
•+ (! - /3)((*i-i - /i)exp(Atj_i) - (ii_2 - /*) exp(At;_2)) 
+ ((*t - //)exp(Aij) - (U-i -•/x)exp(Atj-i))} 
-
 j9fcoMexp(^A*i){(I- /?)iexp(At0) - (1 - £) ' 
• + (1 - ^^HexpCAti) - exp(Ato)) + (1 - PY~2 (exp(Xt2) - exp(Aii)) + . . . 
+ (1 - f3)(exp(\ti-i) - exp(A*i_2)) + exp(Atj) - exp(Aij_i)} 
Pklfj,exp(-\ti){(l - pyn + (1 - py-^to - n)exp(XtQ)(-0) + ... 
+ (tj_i - fi) exp(Xti-i)(-f3) + (U- fi)exp(Xti)} 
- Pk0fiexp{-Xti){-{1- 0Y + (1 - Pf-1 exp(XtQ)(-f3) + ... 
+ exp(Ati_i)(-/3) + exp(Aii)} 
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i - l 
= Pkifiexp(-Xti) { 
+ (U - /J,) exp(XU) J 
(1 - /?)> + ] T ( 1 - py-^itj -
 M)exp(Atj)(-/3) 
j=o 
/3ko/j,exp(-\ti) < 
i - l 
-(1 - W + £ ( 1 - ff-i-iexpiXtjX-P) + expiXti) 
3=0 
Then since tj — \x = to — fi + jA, we can rewrite Di(p) as 
Phut 
i - l 
A*(l - P)1 exp(-XU) - (tQ - //)/?exp(-AA) ] T ( 1 - p)^'1 exp(-X(i - j - 1)A) 
j=0 
i - l 
-APexp(-XA) 2 J'(l - P ) ' " ' " 1 exP(-A(i - j - 1)A) + (U - M) 
- 0kOfi < 
i - l 
- ( 1 - pyexp(-Xti) - pexp(-XA) £ ( 1 ~ /3) i _ J ' - 1 exp(-A(t - j - 1)A) + 1 
j=0 
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Now let Dn = Y^i=i A(/?). Then using the sum of the geometric series 
E?=o ari = a \~i-r)' w e h a v e 
Dn = pkivP^il-Pfexpi-Xti) 
n i—l 
- k^p2(t0 - fi) exp(-AA) J2 £ ( 1 - fly-*-1 exp(-X(i - j - 1)A) 
i = l j = 0 
n i—l n 
- /32fci/xA exp(-AA) E E ^ 1 " 0)<_J '_1 exP(-A(* ~ 3 - 1)A)+ /3fci/i £ > - /*) 
i=i j = i i=i 
n 
+ %^( l - /? ) i exp(-Ai j ) 
i = l 
n i—1 n 
+ /?2fc0/iexp(-AA) Y, E ^ 1 - ^)<"J '"1 exP(~A(* - 3 ~ 1)A) - E £*»/* 
i = l j = o i = l 
n n n 
= pkifi2^Xi - kifiP2{to - /z)exp(-AA) ] £ * i - /32fc1^Aexp(-AA) J^Z i 
i = l i = l t = l 
+ jSfci/i J^(ti - A*) + A%oM Y^Xi + P2***!* e xP(~A A) YlYi~ n^oM, 
i = l i = l i = l 
where 
i = l i = l 
,.
 N , n(n + 1) . 
=
 n(t0 -/*) + - ^ — - A 
n + 1 
= nto-nfi-\ —— (T-to) 
Y^Xi = ^(l-Pfexpi-XU) 
n 
= Y(l-(3yexp(-\(to + iA)) 
i = l 
i=l 
= exp(-\to)J2{(l-P)exp(-\&)y 
l -{ ( l - / ? )exp( -AA)}" 
i = l 
= exp(-Ai0)(l - 0) exp(-AA) 
= exp(-Ai0)(l - P) exp(-AA) 
l - ( l - / ? ) exp ( -AA) 
l-(l-0)nexp(-X(T-to)) 
l - ( l - / 3 )exp( -AA) : 
= EEa-^r^exp^A^-i-^A) 
i=l j=0 
= E Em-^expt-AA)}^-1 
j=Oi=j+l 
^ ! -{(! - /?)exp(-AA)}"-^ 
frf l - ( l - / ? ) exp ( -AA) j=o 
1 - (1 -/?) exp(-AA) { - ^ (l-/?)
wexp(-AA(n)) 
- ( l - /3)exp(-AA) (l-/3)exp(-AA) }' 
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E E ^ 1 - W~~j~l exp(-AA(i - j - 1)) 
i=i j=i 
E i ^ { ( l - ^ e x p l - A A ) } ^ " 1 
"-
1
 l - { ( i - ^ ) e x p ( - A A ) } " ^ 
^V l - U -(l-/3)exp(-AA) 
n(n -
2 
n(n -
• 1 ) 
1) 
n-l 
l - ( l - / ? ) exp ( -AA) 
l - ( l - / ? ) exp ( -AA) 
n - l 
- E "{ (1 -0 ) exp(-AA)}"-'' 
E i { ( l - / 3 ) e x p ( - A A ) } ^ 
n - l 
+ E( n - j ' )K 1 -^ e x p( - A A )} n " J ' 
J=I 
j = i 
i 
l - ( l - /3 )exp( -AA) 
^ { ( l - ^ e x p C - A A ) } " - 1 
—n- l - ( l - /3 )exp( -AA) 
1 f n ( n - l ) 
I n(n_^)
 + g ( n _ j){{1 _ 0) ^^^n-j 
( l - /?)exp(-AA) | 
[ 1 - (1 - P) exp(-AA) t 2 
1 - n{(l - /?) exp(-AA)}"-1 + (n - 1){(1 - (3) exp(-AA)}n 
+ (1-J5)exp(-AA)-
-n ( l - (3) exp(-AA) 
( l - ( l - /3)exp(-AA))2 
l - K l - ^ e x p C - A A ) } " - 1 
1 - ( 1 - P) exp(-AA) 
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Next we rewrite ln(0,t) = E J L Q U - 0Y'j Pj{tj)qj{t - tj) + / ^ w(x)q(t - x)dx. Here, 
we need expressions for Pj(tj)qj(t — tj): 
For j = 0, 
/•to 
Pa(to)qo(t - t0) = / w(x)q(t - x)dx 
Jo 
= / kix\exp(—X(t — x))dx — / &oAexp(—\(t — x))dx 
Jo Jo 
= k\ exp(—Xt){(to — /x) exp(Aio) + p} — ko exp(—\t){exp(\to) — 1}. 
For j > 0, 
rtj 
Pj(tj)qj(t — tj) = / w(x)q(t — x)dx 
Jtj-i 
— I fcixAexp(—\{t — x))dx — I &oAexp(-A(£ — x))dx 
Jtj-i Jtj-\ 
= k\ exp(—Xt){(tj — fi) exp(Afj) — (tj-i — /J.) exp(Xtj-i)} 
— A;oexp(—Ai){exp(Aij) — exp(Aij-i)} 
Also, 
/ w(x)q(t — x)dx = / fcixAexp(—X(t — x))dx — / &oAexp(—X(t — x))dx 
Jti-i Jti~\ Jti~\ 
= k\{t - fx)-ki exp(-A<)(ij_i - n) exp(Ati-i) 
— ko + koexp(-X(t - U-i)). 
Using these expressions we write 
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Ii(P,t) = IX 
*- l rt 
£ ( 1 - W-'PjiWqjit -tj)+ w(x)q(t - x)da 
(1 - p)*{ki exp(-Xt){(t0 - /i) exp(Atp)+/x} - fcoexp(-A*)(exp(Ai0) -1)} 
ao bo 
i - l 
+ V ( l - py-ifa exp(-At){(tj - /x) exp(At,) - (t,_i - ») exp(Xtj-{)} U ' ' a,_i 
— fcoexp(—A£)(exp(At,) — exp(A£,_i))} 
O j - l 
+ k\(t — n) — k\exp(—\t) (tj_i — /i)exp(Atj_i) —fco + fcoexp(—A£)exp(A£j_i) 
o«-i & i - l 
fci exp(-At){(l - PYao + (1 - /?)> + (1 - ^ a i - (1 - /J ) ' " 1^ 
+ (1 - py-2a2 ~ (1 - py-2ai + ., . + (1 - /3)ai_i - (1 - /3)ai_2 - a ^ } 
+
 fcl(t _ M) _ fc0exp(-At){(l - /3)^o - (1 - /?)* + (1 - /3)i_16i - (1 - Z ^ ^ o 
+ (1 - / ? r 2 6 2 - (1 - 0)*-% + . . . + (1 - P)bi-i - (1 - /3)6i_2 - bi-i} - k0 
kx exp(-At){(l - py» + (1 - py~laQ{-p) + .. . + (1 - P)a^2{-P) + Oi_i(-/?)} 
+ *;i(t - /i) - fc0exp(-At){-(i - py + (i - py-%(-p) + ... 
+ (1 - P)bi-2(-P) + bi-xi-P)} - k0 
i-l 
h exp(-Ai) { (1 - /3)V - / ? £ ( 1 - py-i-\ti - /*) exp(Aij) \+ki(t-n) 
+ ko exp(-Ai) < 
i - l 
( l- /?) i + /?]T(l-/?r'-1exp(A* j) >-**>. 
72 
Then integrating out the t, we get 
im = r ii(p,t)dt Jti-i 
rU 
= k\ \ exp(—Xt)dt < 
Jti-i 
rU rU 
+ h(t- n)dt + k0 exp(-Xt)dt 
rU 
— / kodt 
(1 - 0)> - / 3 l > - Py-I-Htj - M)exp(A )^ 
2 - 1 
(l-PY + P^-py-^expiXtj) 
i - l 
*:i/i(exp(-A^i) - exp(-Aii)) < (1 - 0)V - / ? J > - /9)i_J'_1(*j - ^)exp(A^) 
1 j=o 
+ ko/j,(exp(-\ti-i) - exp(-Aij)) { 
- ko(U - ti-i) 
i - l 
(i-py + p^i-py-^expixtj) 
i - l 
= *i/i(l - exp(-AA))exp(-Ai i_i) ^ (1 - /3)V - 0 ^ ( 1 - Py^'^tj - M)exp(Ai,) 
+ 2fci((*» - M) ~ (**—1 - M))((*» - M) + (*i-i - M)) 
i - l 
( l -0)* + /?£;(l-0)<-'-1exp(AtJ-) + /co//(exp(-Aij_i) - exp(-Atj)) ^ 
- fc0(ij - t»_i) 
= fci/z(l - exp(-AA)) I (1 - §)> exp(-A(«i - A)) 
i - l 
- / ? ] > > - Pf-i-^to+jb -
 M)exp(-AA(z - j - 1)) 
+ -fciA(tj + U-\ - 2/*) + fco/*(l - exp(-AA)) {a- /^expf-Afo-A)) 
i - l 
+P £ ( 1 - 0)*-'-1 exp(-AA(i - j - 1)) } - k0(U - U^). 
3=0 
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Now let In = Y%=i Ii(P)- Then 
In = A : i / z 2 ( l - exp( -AA))exp(AA)2( l - /3 ) i exp( -A^) 
i = l 
n i—1 
- ktfuO- ~ exp( -AA))( t 0 - /x) £ ] T ( 1 - / J ) ' " ' " 1 exp(-AA(* - j - 1)) 
i = l j = 0 
n i—1 
- fc!/?M(l - exp(-AA))A £ £ j ( l - /J)*-'"1 exp(-AA(z - j - 1)) 
i=i j = i 
1 n 
+ ^fci A V ( t j + ti_i) - fci/xAn 
n 
+ fco/*(l - exp(-AA)) exp(AA) ] T ( 1 - /?)* exp(-Atj) 
i = l 
n i—1 
+ fco/*/3(l - exp(-AA)) J 2 X ^ 1 ~ £ ) i " J " 1 exp(-AA(i - j - 1)) - fc0A 
i = l j = 0 
n n 
= fciM2(exp(AA) - l) J ] X4 - fclM/3(i0 - /0(1 - exp(-AA)) £ Y, 
i = l i = l 
n .. n 
- fci/i/3A(l - exp(-AA)) YlZi + nklA-S** +-'*-i) ~ fciMAn 
t = l i = l 
n n 
+ fc0/x(exp(AA) - 1) ^ Xi + fco/3^(l - exp(-AA)) ^ Y, - fc0An, 
i = l i = l 
where Xj, Fj, and Z* are defined as before, and 
^(U + U-i) = (h + tn)^ + (to + tn-i)~ 
= (t0 + A + t0 + n A ) | + (tQ + t0 + (n- 1)A)^ 
.= n(2to-\-nA) 
We next use Taylor series expansion to approximate each expression Dn and In. For 
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Dn we expand YA^\ Xii exp(-AA) YH=\ YU and Aexp(-AA) Y!i=\ zi a t z e r 0 : W e u s e 
exp(-AA) = l - A A + y A 2 + 0(A3), 
and let 
9(A) = { ^ ( l - ^ e x p l - A A ) } - 1 
= g(0) + g'(0)A + ^ -A2 + O(A3), 
where 
5(0) = / r 1 
</(A) = _{i_(i_ /3)exp(-AA)}-2{-(l- )a)exp(-AA)}(-A) 
</(0) = -A/T 2 ( l - /3) 
ff"(A) = -A( l - /? )exp(-AA)(-A)( l - ( l -^)exp(-AA))- 2 
- A(l - /?)exp(-AA)(-2)(l - (1 - /3)exp(-AA))-3(-(l - /5)exp(-AA))(-A) 
5"(0) = A2(l - 0)/T2 + 2A2(1 - /?)2/T3 
A2(l-/3)(2-/?) 
Then we can write 
{1-(l-«expMA)}-. _ " . S H S ^ ^ f f l , , , ^ 
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and we also have 
(T-tn) 
(1-/3)" = (l-fls*-
= o(AL) 
for any L > 0. Then we have 
Ex, . .M-^-^M-W-t^XZ^ 
i = l 
= exp(-At0)(l - /?){! - AA + 0(A2)} j ± - ^ - ^ A + 0(A2)} + o(AL) 
.1 — )9 __,
 W W l a^{\(l-P) , A\. A , 0 , . 2 , 
exp(-Ato)-^ - exp(-Ai0)(l - 0) { x ^ ' + -g ) A + O(A )^ 
e x p ( - A f o ) ^ - exp(-Xt0)^-^-A + 0(A2), 
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e x p ( - A A ) ^ y i 
i = i 
exp(-AA) (l-/?)»exp(-A(T-*0)) 
l - ( l - / ? ) exp ( -AA) 
A_2 
2 
1 - (1 - 0) exp(-AA) J, 1 - (1 - 0) exp(-AA) 
exp(-AA) / _ (1 - 0) exp(-AA) 
l - ( l - / ? ) exp ( -AA) 
exp(-AA) 
(l-/3)exP(-AA) 
+ o(AL)} 
0 
0) exp(-AA) 
(l-/?)exp(-AA) 1 
(1 - 0) exp(-AA) 1 - (1 - 0) exp(-AA) 
A + 
} 
+ o(A^)} 
= ( 1 - AA + :± A2 + Q(A3)) ( 1 - h^HA  A2(1 - / p ~ ^  A2 + 0(A3) ) x 
2/33 
{ — G -n + 1 - ( 4 - ^ ^ A + 0(A2)) } + o(AL) /? /?2 
A(l-/3) {^ Q
 + A(^V + ^ + ^ ^ + A 2 ( 1 - / i | 2 - / 3 ) ) A 2 + 0(A3) /?2 A + ^ + /?2 203 >-)A2 + 0 ( A 3 ) } X 
{ T-t0 1-0 \{l-0) A 
T-to 
0 + 02 
'-A + 0(A 2 ) } + o(AL) }  *( 
/3 
+ 0(A 2 ) 
T-to 
H^^M^U) 0{\\ + \(i-0) v 2 ( 2 - / ? ) /?3 + (r-*o)A'^P>-A } 
0 i-{cr-^+y}*{a^a+er-«^a}A+^ 
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and 
Aexp(-AA) ^Zi 
i=\ 
Aexp(-AA) / n ( n - l ) 
l - ( l - /3 )exp( -AA) 
Aexp(-AA) 
+ 
f ( l - f lexp(-AA)
 LA 
l - ( l - / 3 ) e x p ( - A A ) \ ( l - ( l - / 3 ) e x p ( - A A ) ) 2 + ^ }j 
_ Aexp(-AA) f n(l-/3)exp(-AA)
 L/I 
l - ( l - /3 )exp( -AA) \ l - ( l - / ? ) e x p ( - A A ) ^ ;J 
(T-to)exp(-AA) f ( T - t o ) _ 1 \ Aexp(-AA) _
 flW, , A . 
l - ( l - / 3 ) e x p ( - A A ) \ 2A 2 J + (1 - (1 - /?) exp( -AA))3 U ^ e x p l A A ) 
_ (r-*0)exp(-AA) f 1 l U o ( A ^ ) 
l - ( l - / ? ) exp ( -AA) \ l - ( l - / ? ) e x p ( - A A ) J l J 
(T - i0)2 ( l - AA + y A2 + 0(A3)) x 
1 A ( l - / 3 ) A + A 2 ( l - ^ ) ( 2 - / ? ) A 2 + 0 ( A 3 A 1 /3 /32 2/?3 v 7 2A 
- i(T - t„)(l - AA + 0(A2)) ( I - M i ^ 0 A + 0(A2)) 
+A(1 + 0(A))(1 - /J)(l + 0(A))(/T3 + 0(A)) 
- < r - lo)(l - AA + 0(A2)) ( i - ^ ^ A + 0(A2)) x 
(T-tQ)2l (-(T-t0)(l-(3) T-tp (T-t0)2X\ 
2/3 A \ /?2 2/3 2/?2 J 
f ( T - * 0 ) 2 A 2 ( 2 - / ? ) ( r - t o ) A , 1 - /3 „ 2 A ( l - / 3 ) ( r - t 0 ) l A , ^,A 2 X 
+
 \ ~ 4 ^ + 2/?2 + ^ " + & ] A + 0 ( A ) . 
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Thus, omitting terms of 0(A 2 ) , we get 
i = l 
n n n 
= 0kxii2 J^Xi- fciM/?2(*o - /*) exp(-AA) ] T Yt - A i / x A exp(-AA) ^ Z4 
i = l i = l t = l 
+ /?fci^]T(ti - A*) + /?*oM J ] * i + ^ o ^ e x P ( ~ A A ) S Yi ~ J2 PkofX 
i = l i=\ 
= ,Sfci/i2|exp(-Aio) « K -exp(-A*0) v „„ 7 A /32 
+ 
fci/x/32(i0 - fi) I 
2A(l-/3) 
r - i 0 1 
/3 A 
+ (T - to)A2 ( 2 - / 9 ) /33 ' v^ " u / " 2/33 
i = l i = l 
+ ( J 
,2 / ( r - * o ) 2 i , / - ( r - *o ) ( i - / 3 ) 2 T-tp _ (r-*0)2A 
2/3 A V £2 2/3 202 - fci/i/9
2
 ( 
(T-f0)2A2(2-^) , (r-to)A L 1 - j 9 A 2X(l-0)(T-to)\ A | 
+ + 
+ (3k 4 
4/33 ' 2/32 /33 
T - t 0 , (r + i0-2/x)(T-*o) 1 
+ P3 
+ z) 
+ 0koli j exp ( -A to )^ - exp(-A/o)A(1/j ^ A | + koti02 j ^ 2 ^ 
(T-t0)^ + _A 
'/32 
l - / 3 \ / 2 A ( l - / 3 ) 
/?2 ; + v /?3 
= -klfi(3(T-t0)< (t0 -n) + 
,3 + (T - to)A' 
T - to T + t0 - 2/x 
2 ( 2 - 7 ? ) 
2/33 W" 0hn{T-tQ)-
- (3kon(T- to) + /3kov(T - t0) > ! 
+ \ kx^{\ - /3)exp(-At0) + hnP2(tQ -(i)[{T- t0)-, + 
' /32 
klfi [-(T-t0)(l-p) 2 (r-«o) /3-(r- i0)2 A-)+/?M 2 " v u / 2 
+ fco/iexp(-At0)(l— P) ~ koli((f- to)A.+ 1-/3) 
/?2 
(T-to)' 
{-+ < -fci^exp(-At0).A(l- /3) - fci/i(t0 -./*) /2A(l-/3) , A2(T-i0)(2-/3) V 0 4- 2/3 
- M ( ( r - to)2 A 2 ( 2 : ft +• ( r ~ *o)A
 +
 X
-J-+2A(1 ~P){T -to) 4/3 
-k0exp(-\to)(l -0) + fog ^ + ko(T-t0) 
P 0 
X(2-0) 
2/3 h 
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where we recall that A = ^-^•- We may now denote Dn as 
n \n2 
This approximation is more accurate when n is relatively large (or A is small). 
For In we similarly expand (exp(AA) - 1) Y%=\ Xu (1 - exp(-AA)) Y%=i i^> anc* 
A(l - exp(-AA)) Sr=i Zi to get: 
( e x p ( A A ) - l ) ^ X i = (AA + O(A 2 ) ) ( exp ( -Ai 0 ) ^p + O(A)) 
exp(-A^0)A(l-/3)A | 2 
( l - e x p C - A A ) ) ^ ^ 
t = i 
A2 
( AA g ) j w . _ (l-/3)exp(-AA) 1 2 
: p ( - A A ) r l - ( l - / 3 ) e x p ( - A A ) / + U l A j l - ( l - / 3 ) e x t 
- AA ( i + 0(A)) (1 - /?)(! - AA) ( 1 ) + 0(A2) 
- UT M 1 fA2(T-^0) A 2 ( r -^ 0 ) (1- /?) A(l- /3)) 2 
- A(T-i0)--j 2 /? +. ^ - + — ^ — | A + 0 ( A ) , 
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and 
A(l-exp(-AA))J}Zi 
*
2
-A2 (AA - f 2 + 0(A 3 ) ) r 
+ 
l - ( l - / ? ) exp( -AA) 
(l-/3)exp(-AA) 
{•(5-0 
( l - ( l - /3)exp(-AA))2 
( T _ 4 O ) { A A _ | A * } { 1 _ 
(r-^0)2A f(T-
2(3 \ Ap 
n( l - f lexp(-AA) 1
 L 
l - ( l - / 3 ) e x p ( - A A ) J + ° ^ j 
A(l-/3) 
AA 
P2 
- ( 1 
-}(5-i 
P 
An A \ , m • ( 
tQ)2X2 (T-t0)\ 
+
 2p + 
+ 0(A2) 
(1-/?)AA1 
P2 J 
( r - i o ) A ( i - / ? ) . .
 I V V A 2 , 
P2 
+ 0(A2) 
| A + 0 ( A ) . 
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Omitting terms of 0(A 2) gives 
In = Y,h 
i = l 
n n 
= fc1^2(exp(AA)-l)2xi-A:1^(io-/i)(l-exp(-AA))5]yi 
i = l i = l 
n , 
- fci^A(l - exp(-AA)) V Z< + ^ (T2 - t20) - klfi(T - t0) 
n n 
+ fc0/i(exp(AA) - 1) J ^ Xi + k0pfi(l - exp(-AA)) ^Yi - k0(T - t0) 
i=l i = l 
2 / e x p ( - A t 0 ) A ( l - / 3 ) A \ 
= kip P 
| - ( T 2 - t§) - fci/z(T - to) + to e x p ( - A f 0 ) ^ - ^ A + fc0/^ | A ( T - t0)± 
\2(T-t0) X2(T-t0)(l-f3) \(1-P) 
2/3 p2 02 + *v y- ^ ^ A - ^ - t , ) w 
w™, x fci(T-to)2 A ; i ( r 2 - ^ ) ,
 / m 
ffci/xexp(-A*0)(l-/?) fciA(t0-/i)(r-f0)(2-/3) frfa - M)(l - p) 
+
 \ 0 + 2/3 + /3 
hjT-tpfX ki(T - tp)(2 - 0) , fc0exp(-A*0)(l-/3) _ fc0A(r - tp) 
4 2/3 ' /3 . 2 
k0\(T - t0)(l - (3) ko(l-0)\ 
. P P J ' 
where A = ^-^a . We may thus denote In as 
n V r 
Then using the above expressions, we can derive the conditions for the existence of a 
unique maximum of U(n). We have 
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U(n) = Ci{ADn-BIn}-C2(n + l) 
= CXA (a0 + ai^j - CXB (bi^j - C2{n + 1) + .0 (^ 
Now let £ = x and 
h(x) = CiA(a0 + aix) - dB(bix) - C2 (- + 1 
ti(x) = CiAai - Ci-B&i + C2\ 
To find the critical point of h{x) we set h'(x) = 0: 
CiAai - CiBbi + C2X = 0. x2 
The only critical point of h(x), xc, satisfies 
2 &2 
C i ( 5 6 r - i 4 o i ) ' . 
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where 
a! = ( r - ^ o ) U i ( - M e x p ( - A t o ) ( l - / 3 ) - 2 ( t 0 - / , ) - ( 1 " ^ **> ~ AF - U>){2 - 0) 
0 w 
2A(2-/3) _ ( r - t0) _ Ml - P) _ 2(1-0)(T-toy 
4/3 2 /3 /3 
' - to) |fci ( 
~(T-t0) 
= ( r - to) {fca (-/zexp(-Ato)(l - /3) - ( 2 - ^ - *o) ( I ± * - M) 
r - t 0 (2r-/x)(i-/?y 
and 
'-«0){fcl(^ 6! = (T-to) U " ^ T A " + exp(-A*0)( l- /3) A ( t o - ^ ) ( r - t o ) ( 2 - / ? ) ( f 0 - / x ) ( l - / 3 ) /3 2/3 /3 
^r-tp^A
 | ( r - to ) (2-/3) 
+fco 
4 2/3 
/exp(-A* 0 ) ( l - /3) _ A(T - t0) _ - A ( T - fr,)(l - /3) 
V 0 2 /3 ¥)}• 
It is easy to show that a\ < 0 and &i > 0 under the assumption that Is1 < to- This condition 
is easily satisfied under practical settings. Therefore, since 
1. ax < 0, b\ > 0, and ^ > 0, and 
2. h"(x) < 0 for any x > 0, 
C (Bb -/la ) > ^' ^(X) *s c o n c a v e > a n d xc — ycTBb^Aal *s *^e u n i q u e maximum of h(x). 
Equivalently, the optimal A* of the approximate utility function U(n) = C\A(ao + 
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a in) — Ci-^(^in) — Cz(n + 1) c a n be obtained from the optimal n* 
1 n* = — 
fCi(B6i - Aai) 
(r-to) 
rr 
[T-tJ °2 
Ci(Bbi-Aai)' 
In order to have n* > 1, we require 
C2 ~ ' 
This condition is easily satisfied. 
4.2.2 Framework 2: Fixed Budget 
This framework may address a realistic issue of a limited budget of healthcare in 
society. Under a fixed budget, or equivalently a fixed number of examinations, we 
present a utility function where given the starting age t0, the ages of examination 
{ti. ..tn} are unknown. In this scenario, the {£i}i=i...„ which maximize the utility 
function will define the optimal schedule for a prespecified number of exams and 
screening horizon. 
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Presentation of Model 
Using Zelen's expressions for A(/?) and Ii(fi,t), we define the utility function for a 
screening program with n + 1 exams at times to, t\,..., tn as follows: 
U(t\,... ,tn) = Value Of Benefit{t\,... ,tn) — Cost Of Screening(ti,... ,tn) 
( n n+1 \ 
>lJ]A(/3,to,...,*i)-5^/ i( /9,«o,...,<i) -C2(n+1), 
with the first exam at a known age to. Again, we assume that the Benefit is the 
difference in cure rates between those found on examination compared to interval 
cases, where A is the probability of a cure when disease is found through screening, 
B is the probability of a cure for an interval case, C\ is the average dollar value of 
survival benefit due to one life cured, and C2 is the average cost of a screening exam. 
We fix the age of first examination (£0) and the maximum age of examination (T), 
for example t0 = 40 and T = 79 according to current screening guidelines. We are 
thus searching for the optimal schedule of n + 1 examinations at times to, t\, . . . , 
tn which may be unequally-spaced at intervals of Aj, A2, . . . , A„. We can find the 
optimal exam times to, t\, ..., tn < T and therefore the optimal intervals A1( A2, 
. . . , An that maximize the utility function U(ti,..., tn). 
The proof that a solution exists under this framework is simple. 
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Proof for Existence of Solution 
We can prove that U{t\, ...,tn) achieves a maximum at some t\,...,t*n by using the 
Extreme Value Theorem: 
Extreme Value Theorem. Suppose that H is a nonempty subset of Rn and f : 
H —» R. If H is compact, and f is continuous on H, then M := sup{f(x) : x e H} 
and m := m / { / ( x ) : x G H} are finite real numbers. Moreover, there exist points 
x M , xm e H such that M = / (x M ) and m = / (x m ) . 
Clearly, we have a closed and finite set in {(ti,..., tn) : to < t\ < t<i < ... < tn < 
T} since the examination ages are bounded by the starting and ending ages t0 and T. 
It is also clear that since the utility function U consists of continuous functions, it is 
continuous on the compact set {{t\,..., tn) : to < t\ < ti < ... < tn < T}. Therefore, 
a maximum exists at some t\,...,tn. 
4.3 Numerical Results 
We apply the theoretical results to finding the optimal screening program under the 
two separate frameworks. 
4.3.1 Illustration of Framework 1 
To illustrate the results for finding the optimal number of equally spaced exams within 
a fixed screening interval, we specify certain parameter values for the expression U(n). 
We assume that an optimal screening program within a fixed interval [£o, T] will have 
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n + 1 examinations at times to, t\,... ,tn = T in equal intervals of A, where 2^a = n. 
Other parameter assumptions are listed in Table 4.1, which are all based on realistic 
estimators from previous studies. The cure rates A = 0.8 and B = 0.52 were estimated 
based on a long-term follow-up study of survival in breast cancer patients[97j. We 
consider a range of reasonable values for the mean sojourn time and sensitivity of 
mammography examination. The ratio of the cost of examination to value of life 
saved (§*-) is varied at $50, $100, or $200, where we choose value of life saved using 
the commonly accepted threshold stating that a year of life is worth $50,000. Thus 
if the expected gain in survival for screening versus interval detection in a cohort 
of sreened women (who may or may not develop the disease) is 2, 4, or 7 months, 
then the value of life saved is $7,500, $15,000, or $30,000 based on a $50,000 per year 
threshold value. 
Parameter 
Starting age of screening 
Ending age of screening 
Cure rate (screening-detected) 
Cure rate (clinically detected) 
Sojourn time distribution 
Exam sensitivity 
Value of life saved by cure 
Exam cost 
Value 
to = 40 
T = 80 
A = 0.8 
B = 0.52 
Expo(fj), p= {1,2,3} 
0 = {0.7,0.8,0.9} 
d = {$7,500, $15,000, $30,000} 
C2 = $150 
Table 4.1 : Parameter assumptions under Framework 1. 
The values fco and k\ in the preclinical incidence function w(x) are chosen to ap-
proximately reflect an age-dependent incidence function of a population with average-
risk for breast cancer and an increased-risk for breast cancer (Figure 4.1). According 
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to these assumptions, the A (and thus n) that maximizes U was found using the R 
function optimize (Tables 4.2 through 4.4), where the optimal number of examina-
tions n* — 2^a j s rounded down to the nearest integer. A visualization of the utility 
function versus n is shown in Figure 4.2 for the case ^ = 100, (3 = 0.8, and p, = 3 
for the two risk scenarios, showing the concavity of the function. 
Incidence Functions 
in 
d 
— Average Risk Incidence) 
— High-Risk Incidence 
30 40 50 
— I — 
60 
Age (years) 
70 80 90 
Figure 4.1 : Plot of preclinical incidence functions for average- and high-risk groups. 
We observed that the study results are reasonable. The optimal schedule in an 
average-risk population for a mean sojourn time of fj, = 2 in Table 4.2 gives exams in 
approximately one year intervals, which is fairly consistent with current guidelines. 
As the mean sojourn time (fi) increases, A* increases (exams are less frequent). It 
^ = 1 0 = 0.7 
,9 = 0.8 
0 = 0.9 
H = 2 /3 = 0.7 
0 = 0.8 
/? = 0.9 
^ = 3 0 = 0.7 
0 = 0.8 
0 = 0.9 
Increased-Risk 
fc! = 0.0033 
A;0 = 0.112 
n* = 57, A* = 0.699 
n* = 55,A* = 0.716 
n* = 54,A* = 0.738 
n* = 47,A* = 0.840 
n* = 45,A* = 0.888 
n* = 42,A* = 0.939 
n* = 41,A* = 0.963 
n* = 38,A* = 1.031 
n* = 36,A* = 1.102 
Average-Risk 
fci = 0.0028 
fc0 = 0.106 
n* = 42,A* = 0.932 
n* = 43,A* = 0.930 
n* = 42,A* = 0.939 
n* = 37,A* = 1.066 
n* = 36,A* = 1.111 
n* = 34,A* = 1.161 
n* = 33,A* = 1.206 
n* = 33,A* = 1.275 
n* = 29,A* = 1.350 
Table 4.2 : Table of optimal n and Delta under different scenarios for g = $50, or 
equivalently if C2 = $150, then C\ = $7500, or the value of about 2 months. 
fji=l 0 = 0.7 
0 = 0.8 
0 = 0.9 
M = 2 0 = 0.7 
0 = 0.8 
0 = 0.9 
fi = 3 0 = 0.7 
0 = 0.8 
0 = 0.9 
Increased-Risk 
.fci = 0.0033 
k0 = 0.112 
n* = 95,A* = 0.418 
n* = 90,A* = 0.442 
n* = 85,A* = 0.468 
n* = 74,A* = 0.534 
n* = 69,A* = 0.575 
n* = 64,A* = 0.619 
n* = 63,A* = 0.625 
n* = 58,A* = 0.679 
n* = 54, A* = 0.73.7 
Average-Risk 
fci = 0.0028 
k0 = 0.106 
n* = 75,A* = 0.528 
n* = 75,A* = 0.551 
n* = 69,A* = 0.577 
n* = 60,A* = 0.659 
n* = 56,A* = 0.704 
n* = 53,A* = 0.752 
n* = 52,A* = 0.766 
n* = 48,A* = 0.827 
n* = 44,A* = 0.890 
Table 4.3 : Table of optimal n and Delta under different scenarios for §L = $100, or 
equivalently if C2 = $150, then C\ = $15000, or the value of about 4 months. 
90 
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o o in 
High-Risk Scenario 
n*=58, Delta*=0.68 
Avg-Risk Scenario 
n*=48, Delta*=0.83 
30 40 50 60 70 80 30 40 50 60 70 80 
Figure 4.2 : Plots of utility function against n when ^- = $100, (3 = 0.8, /U = 3, under 
the high-risk (h = 0.0033, k0 = 0.112) and average-risk (fcj = 0.0028, A;0 = 0.106) 
scenarios. 
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0 = 1 0 = 0.7 
0 = 0.8 
0 = 0.9 
0 = 2 0 = 0.7 
0 = 0.8 
0 = 0.9 
0 = 3 0 = 0.7 
0 = 0.8 
0 = 0.9 
Increased-Risk 
fci = 0.0033 
k0 = 0.112 
n* = 149,A* = 0.267 
n* = 139,A* = 0.287 
n* = 129,A* = 0.309 
n* = 113,A* = 0.352 
n* = 104,A* = 0.384 
n* = 95,A* = 0.418 
n* = 95,A* = 0.418 
n* = 87,A* = 0.459 
n* = 79,A* = 0.502 
Average-Risk 
Jfei = 0.0028 
k0 = 0.106 
n* = 121,A* = 0.328 
n* = 113,A* = 0.351 
n* = 106,A* = 0.375 
n* = 93,A* = 0.428 
n* = 86,A* = 0.464 
n* = 79, A* = 0.502 
n* = 79,A* = 0.506 
n* = 72,A* = 0.552 
n* = 66,A* = 0.601 
Table 4.4 : Table of optimal n and Delta under different scenarios for ^ = $200, or 
equivalently if Ci = $150, then C\ = $30000, or the value of about 7 months. 
makes sense that if the preclinical duration is longer, examinations may be spaced 
further apart. Also, as the exam sensitivity (0) increases, A* increases. Better exam 
performance may allow for more reliability of the exam and thus less frequent exami-
nations. We also observed that when the incidence is higher, the optimal time between 
examinations is smaller, requiring more frequent examinations among a higher-risk 
group. 
Depending on the ratio of costs ^ , the optimal n and A varied. As the ratio 
increased, the optimal A became smaller. This may reflect that when the value of 
life to be gained is much greater than the cost for screening, there may be more 
incentive to spend more money on additional screening, which leads to more frequent 
and intensive screening exams. > 
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4.3.2 Illustration of Framework 2 
We illustrate the results for finding an optimal set of exam times ti,...,tn < T within 
a screening horizon [t0, T] given the assumptions in Table 4.5. We investigate a range 
of starting and ending ages for screening under various combinations of mean sojourn 
times and exam sensitivities. We illustrate the difference in optimal exam times under 
the given number of exams: 5 and 10 (n = 4,9), using the same estimates of ko and 
k\ for the preclinical incidence w(x) as in the previous illustration. Note that under 
this framework, the optimal exam times do not depend on the costs for exam or life 
value. 
Parameter 
Starting age of screening 
Maximum age of screening 
Cure rate (screening-detected) 
Cure rate (clinically detected) 
Sojourn time distribution 
Exam sensitivity 
Number of Exams 
Value 
t0 = {40,50} 
T = {60,80} 
A = 0.8 
B = 0.52 
Expoin), ^ = {2,4} 
(5 = {0.8,0.6} 
n ' + l = {5,10} 
Table 4.5 : Parameter assumptions under Framework 2. 
Given these assumptions, we use the R function optim to find the set of exam 
times ti,... ,tn that maximize U. The results are listed in Tables 4.6- 4.7. 
We made the following general observations. First, an increase in mean sojourn 
time and exam sensitivity led to an increase in intervals between exams, which again 
makes intuitive sense. It also makes sense that the intervals between exams are shorter 
for shorter screening horizons and longer for longer screening horizons. The intervals 
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between exams consistently decrease with age, as expected. It is interesting to note 
that across the two different risk scenarios, A* decreases under the increased-risk 
scenario for the first interval only, so that the first examination is sooner than in the 
average-risk scenario. The need for screening at an earlier age for higher risk patients 
is thus recognized in the model, although the subsequent exams may not necessarily 
need to be more frequent. 
4.4 Discussion 
We have shown with mathematical proofs that a solution exists for two proposed 
frameworks for finding optimal screening programs under a nonstable disease model 
while incorporating costs, and explored the solutions under various scenarios. Under 
the first proposed framework, we can find the optimal number of examinations (or 
optimal interval between exams) in a given screening horizon, assuming that the 
exams are equally spaced. Under an age-dependent incidence function, equal spacing 
between examinations may not be optimal. However, for policy or administration 
purposes, recommending screening at equal intervals may be more feasible to enforce. 
This framework also accounts for costs of screening and the dollar value of life saved 
by being cured through screening detection versus clinical detection. 
Under the second proposed framework, the optimal ages of examination may be 
found for a specified number of exams within a specified screening horizon. Thus, if 
the number of exams is known, we can find the best times to give them. For example, 
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if a budget exists that can only afford a certain number of exams within a particular 
age interval, then we can find the optimal ages of examination within that interval. 
This may be helpful for healthcare in society, where total funds may be limited. 
Our models are limited since they specify particular forms for the incidence func-
tion and sojourn time distribution. Realistically, a linear assumption for the preclin-
ical incidence may not be practical, and while it has been shown to be a satisfactory 
model, an exponential sojourn time distribution may not necessarily be the best, but 
is practically the only parametric model currently used in the literature. However, 
both assumptions allow for simple derivations of the expressions and make it easier 
to derive the proofs. It may be of interest in future work to explore different para-
metric functions for the preclinical incidence or other representative distributions for 
the sojourn time. 
We also did not account for costs for false-positive exams in the utility functions, 
and did not include a component for competing risks for death. To more realistically 
model the costs and benefits of a screening program, it may be useful to find a way 
to incorporate these issues into the models. 
One other possible adjustment to the model would be to consider the utility as 
a sum of screening and interval detections, rather than a difference. We believe that 
the current work which subtracts interval detections from screening detections better 
reflects the benefit due to screening examinations. The sum of the two terms may be 
considered ion a future analysis as an alternative approach. 
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It should be noted that while the simulation analyses accounted for components of 
discounting of costs and benefits, and lost wages, the utility function presented here 
does not. Thus the two separate approaches should be carefully interpreted given the 
assumptions of each. 
Overall we have explored two possible models for finding the optimal number of 
exams (or equal intervals between exams) or the optimal ages of examinations for a 
specified number of examinations under particular assumptions, namely a nonstable 
disease model. These models may be useful in determining public health recom-
mendations in screening for breast cancer while accounting for the tradeoff between 
costs and benefits, and provide a more global solution to screening policies than a 
simulation-based approach. 
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Chapter 5 
Conclusions 
We have taken both empirical and theoretical approaches to the problem of opti-
mal screening strategies for breast cancer. In the microsimulation models, the anal-
yses are limited to a select set of screening strategies, while the theoretical approach 
has the ability to search for a true global optimum under certain model assump-
tions. In each case, we have explored both approaches in two different risk sets to 
account for differences among the general population and an increased-risk group. 
Both approaches incorporate components that have not been extensively explored in 
the literature. 
For the general population, we conducted a comprehensive microsimulation analy-
sis of the impact of a set of screening strategies on a cohort of women, which included 
all relevant costs from screening to treatment. The screening strategies under consid-
eration included current recommended guidelines from major cancer societies as well 
as combinations of mammography and clinical breast exam. In previous studies, costs 
beyond screening have often been excluded, and the investigated screening programs 
have focused on mammography alone, ignoring the impact of clinical breast exam. We 
found several screening strategies among those studied that were more cost-effective 
compared to the alternatives. The cheapest one was that which offered mammog-
raphy and clinical breast exam in alternating years from ages 40-79, while the most 
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expensive was the recommendation from the American Cancer Society, which begins 
screening with clinical breast exam every three years beginning at age 20, then con-
tinues with both mammography and clinical breast exam annually from ages 40-79. 
Although the American Cancer Society recommendation is more life-saving, the cost 
is very high for a small gain in benefit compared to the cheaper alternatives. If funds 
are not limited, the strategy from the American Cancer Society is favorable, but un-
der a more realistically constrained budget, it may be more cost-effective to select 
the strategy which gives mammography and clinical breast exam from ages 40-79 in 
alternating years. This strategy is still effective, and cheaper, and should be easily 
enforceable in health policy. 
To extend the analysis to an increased-risk population, we made relevant adjust-
ments to the cohort of women according to age-specific incidence and tumor charac-
teristics, and added screening strategies that began screening at an earlier age and 
combined the use of MRI. Although recent developments have led to its recommenda-
tion for women at increased-risk, we found that strategies offering MRI are expensive 
and may not provide much of an increase in survival benefit. In fact, certain strate-
gies offering more frequent mammography alone or mammography and clinical breast 
exam are much cheaper and do not sacrifice much benefit compared to the strategies 
that include MRI. In a high-risk cohort, offering mammography and clinical breast 
exam every six months from ages 30-79 with the addition of annual or biennial MRI 
can be cost-effective. The use of these programs which include MRI depends on 
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society's willingness to pay the high expense for adding MRI to screening policies 
for women of increased-risk for breast cancer. However, the cheaper strategies that 
exclude MRI may actually be favorable, sacrificing only small gains in benefit. 
In future work, we may improve the simulation models by updating them with 
more current data inputs as they become available. The more accurate and current 
the inputs are, the more useful the results may be to health policy makers. There 
are many ways in which the model may be added to or made more complex to more 
accurately represent screening and treatment procedures. For instance, we may want 
to add updated treatment regimens such as axillary or sentinel lymph node dissection, 
and account for possible overdiagnosis due to cases of ductal carcinoma in situ. It 
may also be interesting in a future study to directly incorporate genetic dispositions 
into the microsimulation models to better assess the risk status of each individual in 
the cohort. 
Under the theoretical model, we introduced a utility function that incorporates 
both a nonstable disease model and cost components. Assuming a nonstable disease 
model in place of a stable disease model is more realistic since breast cancer incidence 
has been shown to increase with age. We showed that under two frameworks, a 
solution exists and both give reasonable results. The Equal Intervals model may be 
more practical for use in health policy, while the Fixed Budget model may be useful 
under realistic budget constraints. 
As part of the theoretical model, the use of an alternative preclinical incidence 
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function which better represents the trend in age-specific incidence may be more 
appropriate in future analyses. A linear relationship between incidence and age is 
convenient but may not be realistic. Finally, since our models do not account for 
costs due to false-positive exams or the effects of competing risks, these would be the 
next logical components to be added. 
This work was intended to contribute to decisions in health policy related to the 
early detection of breast cancer. Although this work has focused on breast cancer 
screening, the methods may be applied to the early detection of other cancers or 
diseases with some adjustments to the natural history model or other data inputs 
where necessary. In both the empirical and theoretical approaches, decisions related 
to the tradeoff between reasonable costs and desired benefits must be considered in 
choosing the best screening program. 
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